The QualityStocks Daily Monday, January 23rd, 2023

Today's Top 3 Investment Newsletters

The Stock Dork(INBS) $1.0300 +293.13%

QualityStocks(HLBZ) $0.4260 +109.13%

MarketClub Analysis(VERB) $0.3880 +69.65%

The QualityStocks Daily Stock List

Verb Technology (VERB)

TradersPro, StockMarketWatch, MarketBeat, InvestorPlace, BUYINS.NET, StockWireNews, Small Cap Firm, Fierce Analyst, Broad Street, AwesomeStocks, StockStreetWire, QualityStocks and MarketClub Analysis reported earlier on Verb Technology (VERB), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Verb Technology Company Inc. (NASDAQ: VERB) (FRA: 37V) operates as a Software-as-a-Service applications platform developer internationally as well as in Japan and the U.S.

The firm has its headquarters in American Fork, Utah and was incorporated in 2012 on November 27th by Rory J. Cutaia. Prior to its name change in February 2019, the firm was known as nFusz. It operates as part of the computer software industry in the technology sector, under the software sub-industry.

The company serves the growing CBD industry, clients in the health care industry, not-for-profit organizations, home security firms and real estate companies as well as insurance, auto leasing, auto sales, educational institutions and large professional associations. It has two companies in its corporate family and serves consumers across the globe.

The enterprise provides a live e-commerce application known as verbLIVE and a learning management system application dubbed verbLEARN, which integrates clickable in-video technology featured in its CRM application. It also provides a CRM application (customer relationship management) for solopreneurs and medium and small-scale businesses dubbed verbTEAMS and a CRM application known as verbCRM. In addition to this, the enterprise offers non-digital services to enterprise clients, like printing and design services for starter and welcome kits; subscription-based services; and fulfilment services, such as managing the shipping, handling and/or preparation of custom-branded merchandise.

Many consider the future of e-commerce to be livestream shopping. The company is well-positioned to benefit from the expected growth of live stream shopping in the U.S. given the presence of its verbLIVE application. The company may experience growth as well as an increase in investments as livestream shopping, which is a billion-dollar industry, continues to grow.

Verb Technology (VERB), closed Monday's trading session at $0.388, up 69.6546%, on 145,501,452 volume. The average volume for the last 3 months is 1.166M and the stock's 52-week low/high is $0.1057/$1.69.

GeoMegA Resources, Inc. (GOMRF)

We reported earlier on GeoMegA Resources, Inc. (GOMRF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

GeoMegA Resources, Inc. has developed a proprietary, environmentally friendly “ISR Technology”. This technology recycles rare earth elements with a focus on the permanent magnet industry. The Company produces four high demand, high price, rare earth elements (HHREE – specifically Nd, Pr, Tb, Dy). GeoMegA is progressing towards initial production from its demonstration plant to supply HHREE’s to North America and other parts of the world. Incorporated in 2008, the Company is headquartered in Boucherville and St-Bruno, Quebec.

GeoMegA Resources also owns the Montviel rare earth carbonatite deposit. In addition, the Company holds more than 16.8M shares, representing about 19 percent of the issued and outstanding shares of Kintavar Exploration, Inc. (KTR.V). Kintavar is a mineral exploration company that is advancing the Mitchi stratiform copper project in Quebec.

GeoMegA Resources’ emphasis is sustainable and inventive extraction, separation, and recycling technologies for Rare Earth Element (REE) and other critical metals. As its technologies are demonstrated on larger scales, the Company’s commitment is to work with major partners to help extract value from mining feeds, tailings, and other industrial residues that contain rare earths and other critical metals.

GeoMegA’s core project is based around the ISR Technology (Innord’s Separation of Rare Earths). This is a proprietary, low-cost, environmentally friendly way to tap into a C$1.5 billion global market to recycle magnet production waste and end of life magnets profitably and safely. The Company conducts all of its research and development (R&D) activities through Innord, a wholly-owned private subsidiary and its innovation arm at the National Research Council of Canada (CNRC) facilities in Bouchverville, Quebec. GeoMegA is developing the first rare earth recycling facility in Saint-Bruno-de-Montarville, Quebec.

GeoMegA Resources, Inc. (GOMRF), closed Monday's trading session at $0.1999, up 56.9074%, on 1,165,881 volume. The average volume for the last 3 months is 140.604M and the stock's 52-week low/high is $0.081/$0.2765.

Faraday Future Intelligent Electric (FFIE)

Schaeffer's, MarketClub Analysis, QualityStocks, Trades Of The Day, The Street, The Stock Dork, Penny Stock, MarketBeat, Early Bird and Daily Trade Alert reported earlier on Faraday Future Intelligent Electric (FFIE), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Faraday Future Intelligent Electric Inc. (NASDAQ: FFIE) is a mobility ecosystem firm that is focused on designing, developing, manufacturing, engineering, selling and distributing electric vehicles and related products.

The firm has its headquarters in Gardena, California and was incorporated in May 2014. Prior to its name change, the firm was known as Property Solutions Acquisition Corp. It operates as part of the auto manufacturers industry, under the consumer cyclical sector. The firm serves consumers around the globe.

The company’s objective is to improve the way individuals move by creating a forward-thinking mobility ecosystem which integrates new usership models, the internet, artificial intelligence and clean energy.The company unites the latest in sustainable transportation and connected digital ecosystems.

The enterprise has pioneered a number of innovations relating to its business model, products, technology and user ecosystem. It develops in-vehicle content, ownership models and autonomous driving technologies. The enterprise’s first production vehicle and flagship model is the FF 91. The FF 91 Futurist models and Alliance Edition represent the next generation of intelligent tech-luxury electrical vehicles. These high performance electric vehicles enable users to experience a high-tech, luxurious 3rd internet living space, beyond their office and home.

The firm recently received intelligent manufacturing equipment from a top-tier automotive supplier, Guangzhou MINO Equipment Co. Ltd. The equipment is to be used in the development of the firm’s vehicles, which are set to redefine the luxury electric vehicle segment in the electric vehicle industry. This will not only bring in additional revenue into the firm but also positively impact its growth.

Faraday Future Intelligent Electric (FFIE), closed Monday's trading session at $0.9237, up 50.636%, on 141,733,783 volume. The average volume for the last 3 months is 2.959M and the stock's 52-week low/high is $0.245/$7.85.

Inspira Technologies (IINN)

MarketClub Analysis, QualityStocks and RedChip reported earlier on Inspira Technologies (IINN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Inspira Technologies Oxy B.H.N Ltd (NASDAQ: IINN)is a specialty medical device firm that is focused on researching, developing, manufacturing and marketing respiratory support technologies that offer alternatives to invasive mechanical ventilation used to treat respiratory failure.

The firm has its headquarters in Ra’annana, Israel and was incorporated in July 2017. Prior to its name change in July 2020, the firm was known as Insense Medical Ltd. The firm serves consumers around the globe.

The company’s goal is to develop a less-invasive and cost-effective respiratory support system that can act as an alternative to the mechanical ventilation that’s currently being used to save the lives of individuals with acute respiratory failure. Acute respiratory failure happens when there’s fluid buildup in the air sacs of an individual’s lungs, thus preventing their lungs from releasing oxygen into the blood.

The enterprise’s products include its new technology dubbed ART (Augmented Respiration Technology system). This respiratory support system is made up of a portable and minimally invasive dual lumen cannula, which is usually inserted into the jugular vein. This cannula uses extra-corporeal direct blood oxygenation to boost and stabilize dropping levels of oxygen saturation. This system helps to avoid the risks associated with the use of mechanical ventilation while also allowing patients to maintain spontaneous breathing.

The company recently entered into an exclusive distribution agreement with Anita Técnica S.L., which is a technical service provider and distributor of medical equipment and supplies in Spain and Portugal. This move will facilitate the rapid penetration and adoption of the company’s ART system in the medical community in Spain, which may bring in more investors into the firm and boost the company’s growth.

Inspira Technologies (IINN), closed Monday's trading session at $1.87, up 49.6%, on 2,959,357 volume. The average volume for the last 3 months is 900 and the stock's 52-week low/high is $0.98/$3.54.

Silex Systems (SILXF)

We reported earlier on Silex Systems (SILXF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Silex Systems Limited (OTCQX: SILXF) (ASX: SLX) (FRA: RW4) is a technology commercialization firm that is focused on conducting research on, developing, commercializing and licensing SILEX laser uranium enrichment technology.

The firm has its headquarters in Sydney, Australia and was incorporated in 1988 by Michael P. Goldsworthy. It operates as part of the semiconductors industry, under the technology sector. The firm serves consumers around the globe.

The company is party to an exclusive license agreement with Global Laser Enrichment LLC, which entails the commercialization of its uranium enrichment application. It operates through the Silex Systems, Translucent and Silex USA segments. The company generates maximum revenue from the Silex Systems segment.

The enterprise is focused on the commercialization of its Separation of Isotopes by Laser EXcitation (SILEX) laser enrichment technology for uranium production and enrichment (nuclear power), silicon enrichment (silicon quantum computing) and other potential markets, which includes medical radioisotopes. Its SILEX Zero-Spin Silicon (ZS-Si) project is being undertaken with project partners, UNSW Sydney (UNSW) and Silicon Quantum Computing Pty Ltd (SQC) at its Lucas Heights facility. It also has an interest in a semiconductor technology known as cREO through its wholly-owned subsidiary, Translucent Inc. This is in addition to developing semiconductor technology for 5G mobile handset filter application.

The firm, which recently gave an update on its uranium enrichment technology project, remains committed to its strategy to extract maximum value from its core SILEX technology and expertise. This will help generate value for its shareholders.

Silex Systems (SILXF), closed Monday's trading session at $3.2, up 4.918%, on 900 volume. The average volume for the last 3 months is 500 and the stock's 52-week low/high is $0.74725/$3.25.

Karoon Energy (KRNGF)

We reported earlier on Karoon Energy (KRNGF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Karoon Energy Ltd (OTC: KRNGF) (ASX: KAR) (FRA: LBL) is an oil and gas exploration and production firm that is focused on exploring for and acquiring natural resource properties.

The firm has its headquarters in Southbank, Australia and was incorporated in 2003, on November 11th by Robert Michael Hosking. Prior to its name change in December 2018, the firm was known as Karoon Gas Australia Limited. It operates as part of the oil and gas E&P industry, under the energy sector. The firm serves consumers around the globe.

The enterprise holds 100% interest in the Santos Basin, which comprises of 5 off-shore blocks located roughly 200 km off the coast in the State of Sao Paulo, Brazil. It has also acquired 100% of the early-stage exploration permit WA-482-P in the Carnarvon Basin, which it holds 50% interest in and is located in north Western Australia. The enterprise also holds 40% interest in the Tumbes Basin, which covers an area of about 4,875 km2 located 10 km offshore from the coast of northern Peru, 56 km west of the city of Tumbes and 39 km west of Caleta Cruz. Its Bauna-Santos Basin project is located in concession BM-S-40, in the southern Santos Basin and consists of the Bauna and Piracaba light oil fields and the Patola oil discovery, which is currently being developed. The enterprise’s exploration permit covers roughly 17,793 km2 of the Ceduna Sub-Basin. It generates revenue from crude oil sales.

The company’s latest financial and operational results show increases in its oil sales revenue and production volumes. It remains committed to creating a reliable and sustainable base business that can provide returns to shareholders as well as a foundation for further growth.

Karoon Energy (KRNGF), closed Monday's trading session at $1.45, even for the day. The average volume for the last 3 months is 35 and the stock's 52-week low/high is $0.99/$1.765.

Emerald Resources (EOGSF)

We reported earlier on Emerald Resources (EOGSF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Emerald Resources NL (OTC: EOGSF) (ASX: EMR) is a mining firm focused on exploring for and developing mineral reserves in Australia and Cambodia.

The firm has its headquarters in West Perth, Australia and was incorporated in 1969. Prior to its name change in December 2014, the firm was known as Emerald Oil & Gas NL. It operates as part of the gold industry, under the basic materials sector. The firm serves consumers around the globe, with a focus on those in Australia and Cambodia.

The enterprise’s projects include Okvau Gold project, Memot Gold project, and Preak-Klong Gold project. It is primarily focused on the development and commissioning of its advanced project, the Okvau Gold Mine in Cambodia. This gold mine is located approximately 275 km northeast of Cambodia’s capital city of Phnom Penh in the province of Mondulkiri. The enterprise holds a range of other projects in Cambodia, which are comprised of a combination of granted mining licenses (100% owned by the firm) and interests joint venture agreements. Together, Emerald’s interest in its Cambodian Projects covers a combined area of approximately 1,239 km2. The enterprise also has a 5% overriding royalty interest in all gas production from various oil and gas interests located in Magoffin County, Kentucky.

The company, which recently announced that its gold production had hit a new high, remains focused on growing shareholder value through the identification of suitable advanced gold development projects. This will positively influence investments into the company as well as its growth.

Emerald Resources (EOGSF), closed Monday's trading session at $0.9798, even for the day, on 35 volume. The average volume for the last 3 months is 1,025 and the stock's 52-week low/high is $0.3615/$1.52.

Beijing Gas Blue Sky Holdings (BJGBF)

We reported earlier on Beijing Gas Blue Sky Holdings (BJGBF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Beijing Gas Blue Sky Holdings Limited (OTC: BJGBF) (HKG: 6828) (FRA: KO32) is an investment holding firm that is focused on selling and distributing natural gas and other related products.

The firm has its headquarters in Central, Hong Kong and was incorporated in October 2000. Prior to its name change in January 2017, the firm was known as Blue Sky Power Holdings Ltd. It operates as part of the utilities-regulated gas industry, under the utilities sector. The firm serves consumers in the People’s Republic of China.

The company operates through the Natural Gas for Transportation; Trading and Distribution of Natural Gas; and City Gas and Other Related Products segments. The Natural Gas for Transportation segment is involved in the operation of compressed natural gas (CNG) and liquefied natural gas (LNG) refueling stations for vehicles. The Trading and Distribution of Natural Gas segment is focused on the trade and distribution of CNG and LNG as a wholesaler and sales agent to industrial and commercial users through direct supply facilities. The City Gas and Other Related Products segment is involved in the sale of natural gas to residential, industrial and commercial users through pipelines, pipeline connection fees and other related products, such as sale of electricity, transportation income, rental income and other income from value-added services.

The enterprise also sells natural gas to residential, industrial, and commercial users through pipelines. It is also involved in the provision of repair and maintenance, and pipeline construction. It owns 29 gas refueling stations, including 17 CNG refueling stations and 12 LNG refueling stations.

The company remains focused on accelerating the expansion of its business operations globally, which will positively influence its growth, investments into the company as well as shareholder value.

Beijing Gas Blue Sky Holdings (BJGBF), closed Monday's trading session at $0.0522, even for the day. The average volume for the last 3 months is 183,981 and the stock's 52-week low/high is $0.02/$0.0528.

PetroTal (PTALF)

MarketBeat reported earlier on PetroTal (PTALF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

PetroTal Corp. (OTCQX: PTALF) (LON: PTAL) (CVE: TAL) (FRA: SER1) is an oil and gas firm that is focused on exploring for, appraising and developing crude oil and natural gas assets.

The firm has its headquarters in Houston, Texas and was incorporated in 2017, on December 18th. Prior to its name change in June 2018, the firm was known as Sterling Resources Ltd. It operates as part of the oil and gas E&P industry, under the energy sector. The firm serves consumers in North and South America.

The company’s management team has significant experience in developing oil fields in Northern Peru and is focused on safely and cost effectively developing and exploiting the Bretaña oil field. It operates through its subsidiaries, which include PetroTal USA Corp., PetroTal Energy International (Peru) Holdings B.V., PetroTal LLC, Petrolifera Petroleum Del Peru S.R.L., PetroTal Peru B.V. and PetroTal Peru S.R.L. The company generates revenues from the sale of crude oil.

The enterprise’s primary asset is the Bretana oil field located in the Marañón Basin of northern Peru. It has two operations; Block 95 and Block 107. Its Block 107 operation is located in the Ucayali basin, which contains the Osheki prospect and fields. As of 2022, production for Bretaña was estimated to exceed 20,000 barrels of oil per day. The field holds over 100 million barrels of oil on a 3P basis making it a significant resource for the firm to produce from for years to come even after reaching peak production.

The firm, which recently announced a corporate update, remains focused on enhancing its export capabilities to produce at full capacity. This will positively influence revenues and investments into the firm as well as its overall growth.

PetroTal (PTALF), closed Monday's trading session at $0.54, up 1.4275%, on 183,981 volume. The average volume for the last 3 months is 719,517 and the stock's 52-week low/high is $0.361165/$0.78565.

Calix Inc. (CALX)

MarketBeat, All about trends, TradersPro, MarketClub Analysis, Schaeffer's, Zacks, Daily Trade Alert, StreetInsider, Street Insider, SmarTrend Newsletters, Marketbeat.com, The Street, StockMarketWatch, Trades Of The Day, InvestorPlace, Stocks That Move, Kiplinger Today, InvestorsObserver Team, Hit and Run Candle Sticks, Greenbackers, Dynamic Wealth Report, DrStockPick, WStreet Market Commentary, BUYINS.NET and RedChip reported earlier on Calix Inc. (CALX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Calix (NYSE: CALX) was featured in a recent equity research report published by Roth Capital Partners LLC. An excerpt of the report reads, “We expect Calix to report meet or beat 4Q22 results (1/26 BMO) driven by continued strong demand of the ongoing broadband ‘super cycle’ (unmet demand, increasing broadband requirements and a favorable regulatory environment). Misconstrued comments around macro supply chain issues have driven the stock down 18% since Jan 10th. Demand and supply are not the constraints, but rather skilled labor for deployments (this is nothing new). We would use the weakness as an entry point into the print.”

To request access to the full report, visit https://ibn.fm/z0W2k

About Calix Inc.

The cloud and software platforms offered by Calix enable service providers of all types and sizes to innovate and transform. The company’s customers utilize the real-time data and insights from these platforms to simplify their businesses and deliver experiences that excite their subscribers. The resulting growth in subscriber acquisition, loyalty, and revenue creates more value for their businesses and communities. This is the Calix mission: To enable broadband service providers of all sizes to simplify, excite, and grow. For more information, visit the company’s website at www.Calix.com.

Calix Inc. (CALX), closed Monday's trading session at $58.33, up 2.3513%, on 726,035 volume. The average volume for the last 3 months is 177,637 and the stock's 52-week low/high is $31.59/$77.44.

Kandi Technologies Group Inc. (KNDI)

Green Car Stocks, MarketClub Analysis, InvestorPlace, Schaeffer's, QualityStocks, The Street, StockMarketWatch, Hit and Run Candle Sticks, StreetInsider, TraderPower, Greenbackers, Jason Bond, Alternative Energy, GreatStockPix, Wall Street Resources, China Stock Alerts, MarketBeat, BUYINS.NET, Investing Futures, Marketbeat.com, Money Morning, Penny Stock Rumble, ProfitableTrading, TradersPro, SmarTrend Newsletters, StreetAuthority Daily, Trades Of The Day, TradingMarkets, TopStockAnalysts, FeedBlitz, Energy and Capital, Dynamic Wealth Report, DrStockPick, Money and Markets, CRWEWallStreet, Street Insider, CRWEPicks, CRWEFinance, CoolPennyStocks, ChartAdvisor, Weekly Wizards, BullRally, BestOtc, Barchart, Daily Trade Alert, StockEgg, Profit Confidential, PennyTrader Publisher, PennyToBuck, PennyStockVille, PennyOmega, PennyInvest, SmallCapNetwork, SmallCapVoice, HotOTC, Stock Traders Chat, INO.com Market Report, MadPennyStocks, StockHotTips, InvestorsUnderground, Investors Alley, StockRich, InvestorGuide, Investor Ideas, Rick Saddler and Willy Wizard reported earlier on Kandi Technologies Group Inc. (KNDI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Electric vehicles are regarded as a crucial strategy to minimize emissions that contribute to global warming. As per the Kelley Blue Book, a brand-new electric car cost more than $65,000 on average last year. However, even if operating costs are lower than those of a gas-powered vehicle, there are still additional expenditures involved with EVs, such as tax and insurance costs, as well as parking fees.

Lelac Almagor, from Washington, DC, a mother of three who owns an electric bike, believes there is another way to stop relying on a fuel vehicle — riding an electric bike. E-bikes slash the effort needed by the rider, or in certain situations, they can even  take full control using a battery together with an electrical motor.

The Bureau of Transportation Statistics found that in 2021, 52% of the trips taken were less than three miles, which is a short distance that the majority of people could actually complete on an electric bike. As a result, the city and county of Denver are offering coupons toward purchasing an electric bike.

The coupons provide typical residents of Denver $400 for an electric bike; those who qualify as low-income earners receive $1,200. This sum is almost equivalent to the cost of a basic electric bike; e-bikes are priced higher than the majority of ordinary bikes. The residents would receive an extra $500 if they chose an electric cargo bike, the type suitable in substituting car rides.

The coupons were extremely well received and helped convince more individuals to purchase electric bikes. The preliminary findings indicate that the Denver voucher program is having the desired impact.

During Earth Day last year, the Denver initiative was introduced, and it will recommence at the close of January this year. The value of this year’s voucher will be less to allow the city to include more new electric bike users in their financing.

Bike enthusiasts, including Noa Banayan of People for Bikes, support  federally funded incentives. Banayan hopes that legislators in Washington will approve e-bike incentives similar to those offered to buyers of electric vehicles.

Skyler McKinley from AAA Colorado thinks that those who live in remote regions will present a challenge to the use of e-bikes. According to him, fossil fuel-dependent vehicles will probably continue to be the popular choice for some time given the high cost of EVs. He further advises that there is absolutely no need for a car excursion if you reside in an urban center and need to travel to a shop that is only two miles’ distance to buy some food. Just purchase a cargo electric bike so you can complete that work as fast, securely and conveniently as you could with a car, he explains.

The growing popularity of e-bikes is unlikely to dent the escalating demand for EVs made by various startups such as Kandi Technologies Group Inc. (NASDAQ: KNDI) because e-bikes have their own limitations and customer preferences differ.

Kandi Technologies Group Inc. (KNDI), closed Monday's trading session at $2.8, up 2.9412%, on 178,052 volume. The average volume for the last 3 months is 23.368M and the stock's 52-week low/high is $2.00/$3.75.

RIOT Blockchain Inc. (RIOT)

Schaeffer's, MarketClub Analysis, StocksEarning, InvestorPlace, StockMarketWatch, QualityStocks, MarketBeat, TradersPro, Zacks, Market Intelligence Center Alert, The Street, Kiplinger Today, The Online Investor, TraderPower, Trades Of The Day, BUYINS.NET, Daily Trade Alert, Market Intelligence Center, InvestorsUnderground, StreetAuthority Daily, AllPennyStocks, PennyStockLocks, Trading Tips, StockRockandRoll, Penny Stock 101, BillionDollarClub, TopPennyStockMovers, Early Bird, The Daily Market Alert, Promotion Stock Secrets, StreetInsider, Louis Navellier, StockEarnings, Money Morning and Investors Alley reported earlier on RIOT Blockchain Inc. (RIOT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

A cannabis nursery based in Mendocino County, California, has adopted the use of blockchains as well as smart contracts to authenticate its medicinal herbs. Called Mendocino Clone, the nursery was mentioned in a partnership project with EMTRI and tech company Global Compliance Applications earlier this month. It now has the power to harness the blockchain capabilities of the project to be able to ratify all clones or plants from its inception stages using a batch certificate.

Cannabis nursery establishments specialize in plant biology (genetics), cloning of the plants, and recording shoots and seeds for wholesale distribution purposes. This move gives room for nurseries to collect data beginning at the inception stages of a cannabis plant through when the premium cannabis flower arrives to the consumer, based on its weight in grams.

These batch certificates are self-generated through a smart contract for every clone batch. This makes each clone plant peculiar, owing to the unique identity block that the nursery has created and linked to Ethereum blockchains. The nursery’s clients will therefore be able to certify the clone’s authenticity as well as the clone plants’ genetic lineage. The maiden batch’s certificates should be out beginning February.

Also, licensed cannabis farmers who will buy Mendocino clones shall be granted access to EMTRI rewards (tokens) and fairer rates when participating in the project. In November, the EMT was launched to reward the project participants with tokens. These tokens can be exchanged or traded on Uniswap for USDC or pledged for further benefits. EMT is not on any Bourse platform or crypto markets such as CoinGecko.

EMTRI cofounder Scott Zarnes said that the organization was excited to be a front-runner in adopting cutting-edge technology in the U.S. cannabis industry. It is known for a fact that the crypto and cannabis amalgamation is not a new phenomenon in the market.

In November last year, a Metaverse cannabis-themed project named Cannaland was set in motion to make room for a virtual world specific to cannabis enthusiasts. Early last year, a bespoke pipe maker availed tokenized pipes with the likes of Snoop Doggy Dogg grabbing up the NFTs.

PotCoin (aka POT) as well as CannabisCoin (aka CANN) type of projects have purposed to aid in creating a digital legal tender specific to the cannabis industry dating as far back as 2014, but they were not successful in the venture.

These growing use cases for blockchain technology are making the public increasingly accepting of companies such as RIOT Blockchain Inc. (NASDAQ: RIOT), since the members of the public can see how the tech is penetrating every aspect of their lives as time goes by.

RIOT Blockchain Inc. (RIOT), closed Monday's trading session at $6.48, up 4.5161%, on 23,506,125 volume. The average volume for the last 3 months is 1.562M and the stock's 52-week low/high is $3.25/$23.66.

The QualityStocks Company Corner

Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR)

The QualityStocks Daily Newsletter would like to spotlight Energy Fuels Inc. (UUUU).

West Virginia is poised to play a major role in green energy afterthe state lifted a ban on the construction of nuclear power plants last February. As America and the world at large go through one ofthe most debilitating energy crunches in recent history, statessuch as West Virginia will allow the nation to make its energy mixgreener while reducing reliance on imported energy from countriessuch as Russia. During a recent visit to West Virginia, Bill Gates noted that the state had a “unique opportunity” tobuild on its history of energy production and take the lead in thecountry’s transition to clean energy. Gates toured a former powerplant in Glasgow in his capacity as the founder of Breakthrough Energy, an organization with the aim of accelerating innovation insustainable energy to cut down greenhouse gas emissions. Sen. JoeManchin, who chairs the Energy and Natural Resources Committee ofthe Senate and was instrumental in the passage of the Inflation Reduction Act, hosted the former Microsoft CEO. Gates said that the clean-energyindustries in the state are “positioned for rapid growth” due tohistoric investment by the government and technological progressover the past few decades. As more retired coal plants areretrofitted into nuclear energy facilities, the local demand forthe uranium extracted by enterprises such as Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) can only keep growing, leading to a robust domestic industry.

Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR),based in Lakewood, Colorado, is the country’s largest producer of uranium and the leading conventional producer of vanadium, both designated by the U.S. government as critical minerals.

As the leading U.S. diversified uranium miner, Energy Fuels’ uranium production portfolio stands apart in the world. Energy Fuels has more uranium production facilities, more production capacity, and more in-ground resources than any other company in the United States. In fact, the company’s assets have produced over one-third of all U.S. uranium over the past 15 years and is uniquely positioned to increase production to meet new demand.

Energy Fuels utilizes both conventional and in-situ recovery (“ISR”) technology to produce uranium from three strategic facilities:

  • White Mesa Mill in Utah (conventional) has a licensed capacity of over 8 million pounds of U3O8 per year. The highly strategic White Mesa Mill is the only conventional uranium mill in the country and is proximate to some of the largest and highest-grade uranium mines and projects in the U.S., including the Company’s Canyon mine, La Sal Complex, Henry Mountains Complex and Roca Honda Project. White Mesa Mill provides Energy Fuels with significant production scalability as uranium demand increases. The White Mesa Mill also has other diverse businesses, including vanadium, rare earth elements (REE’s), alternate feed materials recycling and land cleanup, all described below.
  • Nichols Ranch Plant (ISR) is located in the productive Powder River Basin district of Wyoming and has a total licensed capacity of 2 million pounds of U3O8 per year. Nichols Ranch has produced 1.2 million pounds of U3O8 since commissioning in 2014, and it has significant future expansion potential from 34 fully licensed wellfields containing significant in-ground uranium resources.
  • Alta Mesa Plant (ISR) is located on over 200,000 acres of private land in Texas. The fully licensed and constructed ISR project has a total operating capacity of 1.5 million pounds of uranium per year and produced nearly 5 million pounds of U3O8 between 2005 and 2013. This low-cost production facility is currently on standby, maintained in a state of readiness to respond to expected increases in demand.

In addition to being the largest uranium miner in the U.S., Energy Fuels’ overall portfolio also includes a pipeline of high-quality, large-scale exploration and development projects that are permitted or are in advanced stages of permitting, as well as an industry-leading U.S. NI 43-101 Mineral Resource portfolio.

FACTOID: Energy Fuels has led industry efforts over the past two-plus years to get the U.S. government to recognize the importance of domestically produced uranium, including the 2018 – 2019 Uranium Section 232, the ongoing Nuclear Fuel Working Group and the recently announced creation of the U.S. strategic uranium reserve. The U.S. is by far the largest consumer of uranium in the world, yet we import almost all of our requirements; Energy Fuels aims to change that.

Nuclear Market Potential

Multiple studies in top scientific journals have shown that nuclear power is cleanest and most economical way to produce reliable electricity as worldwide demand continues to soar. Nuclear power is presently the only available and affordable low-carbon power source that can meet both current and future baseload electricity demands while simultaneously reducing air pollution and mitigating climate change. U.S. nuclear power plants currently generate nearly 20% of the nation’s electricity overall and 55% of its carbon‐free electricity and even a modest increase in electricity demand would require significant new nuclear capacity by 2025. According to the World Nuclear Association (WNA), there are currently 441 operable reactors, with another 54 units under construction and 439 in various stages of planning; in addition, the WNA has identified a potentially massive supply/demand gap through 2040 of 1 billion pounds. These factors among others are expected to significantly drive increased demand for uranium.

Reasons Nuclear is Gaining Traction

  • Nuclear reactors emit no greenhouse gases during operation. Over their full lifetimes, they result in comparable emissions to renewable forms of energy such as wind and solar.
  • Unlike any other form of energy, the waste from nuclear energy is contained and managed securely. Used fuel is currently being safely stored for ultimate disposal or future reprocessing, and 96% of this waste can potentially be recycled.
  • Greater demand for clean electricity to power everything from homes to automobiles, reducing dependence on fossil fuels.

No. 1 U.S. Producer of Vanadium in 2019

Energy Fuels also produces vanadium as a byproduct of uranium production. Vanadium is designated a critical mineral, essential to the economic and national security of the United States. Energy Fuels was the largest producer of vanadium in the U.S. in 2019, and has significant high-grade, in-ground vanadium resources, as well as a separate high-purity vanadium production circuit at their White Mesa Mill, which is also the only conventional vanadium mill in the country. Crucial for use in the steel, aerospace, and chemical industries, vanadium plays a critical role in the production of high-strength and light-weight metallic alloys and demand is expected to increase across the globe.

Energy Fuels has several fully permitted and developed standby mines containing large quantities of high-grade vanadium, along with uranium, including:

  • La Sal Complex (Utah)
  • Whirlwind Mine (Colorado/Utah)
  • Rim Mine (Colorado)

Vanadium has also gained increased attention as a catalyst in next-generation high-capacity, “community-scale” batteries used for energy storage generated from renewable sources. Demand is only expected to grow as this market expands. With recent upgrades in its vanadium production operations, in 2019 Energy Fuels produced commercial levels of the highest purity (99.7%) vanadium in the mill’s history and can rapidly adjust production to meet volatile market conditions. Energy Fuels is one of the very few known avenues that provides investors access the vanadium market.

Rare Earth Element (REE) Production, Alternate Feed Material Recycling, and Land Cleanup

The White Mesa Mill also provides the company with diverse cashflow generating opportunities. Security of supply for Rare Earth Elements (REEs) supporting U.S. military and defense requirements is a major issue today. Energy Fuels has been approached by a number of entities, including the U.S. government, inquiring about the potential to process certain REEs at the mill. The White Mesa Mill is currently licensed to process certain REEs, including tantalum and niobium. And, early indications are that the mill can be utilized to produce several other REEs. The White Mesa Mill is also the only facility in North America licensed and capable of recycling alternate feed materials (AFMs). AFMs are essentially low-level waste materials that contain recoverable quantities of natural (or unenriched) uranium. The Company typically generates between $5 and $15 million per year from AFM recycling. Finally, Energy Fuels is seeking to become involved in the cleanup of legacy Cold War era uranium mines in the Four Corners region of the U.S., including on the Navajo Nation. The U.S. Environmental Protection Agency (EPA) has access to over $1.5 billion for the cleanup of just a fraction of the sites on the Navajo Nation. The White Mesa Mill is fully licensed to receive much of this material, we are one of the government’s lowest cost options, and we have the ability to recycle the material and produce usable uranium from it.

Management Team

Mark S. Chalmers, President and CEO
Mark S. Chalmers is the president and chief executive officer of Energy Fuels, a position he has held since Feb. 1, 2018, following his role as chief operating officer of Energy Fuels from July 1, 2016 – Jan. 31, 2018. From 2011 to 2015, Chalmers served as executive general manager of Production for Paladin Energy Ltd., a uranium producer with assets in Australia and Africa, including the Langer Heinrich and Kayelekera mines where, as head of operations, he oversaw sustained, significant increases in production while reducing operating costs. He also possesses extensive experience in in situ recovery (“ISR”) uranium production, including management of the Beverley Uranium Mine owned by General Atomics (Australia), and the Highland mine owned by Cameco Corporation (USA). Chalmers has also consulted to several of the largest players in the uranium supply sector, including BHP Billiton, Rio Tinto, and Marubeni, and until recently served as the chair of the Australian Uranium Council, a position he held for 10 years. Chalmers is a registered professional engineer and holds a Bachelor of Science in Mining Engineering from the University of Arizona.

W. Paul Goranson, COO
W. Paul Goranson is the chief operating officer for Energy Fuels. Goranson has 30 years of mining, processing and regulatory experience in the uranium extraction industry that includes both conventional and in-situ recovery (“ISR”) mining, and he is a registered professional engineer. Prior to the acquisition by Energy Fuels of Uranerz Energy Corporation, Goranson served as president, chief operating officer and director for Uranerz, where he was responsible for operations of the Nichols Ranch ISR Uranium Project. In addition to those duties, he also managed uranium marketing, regulatory and government affairs, exploration and land. Prior to joining Uranerz, Goranson served as president of Cameco Resources, where he led the operations at the Smith Ranch-Highland, Crow Butte and North Butte ISR uranium recovery facilities. Goranson also served as vice president of Mesteña Uranium LLC, and he has served in senior positions with Rio Algom Mining, (a subsidiary of BHP Billiton), and Uranium Resource Inc. Goranson has a Bachelor of Science in Natural Gas Engineering from Texas A&I University, and a Master of Science in Environmental Engineering from Texas A&M University-Kingsville.

David C. Frydenlund, CFO, General Counsel, Corporate Secretary
David C. Frydenlund is chief financial officer, general counsel, and corporate secretary of Energy Fuels. His responsibilities include oversight of all legal matters relating to the company’s activities. His expertise extends to NRC, EPA, state and federal regulatory and environmental laws and regulations. From 1997 to 2012, Frydenlund was vice president of regulatory affairs, general counsel and corporate secretary of Denison Mines Corp., and its predecessor International Uranium Corporation (“IUC”). He also served as a director of IUC from 1997 to 2006 and CFO of IUC from 2000 to 2005. From 1996 to 1997, Frydenlund was vice president of the Lundin Group of international public mining and oil and gas companies, and prior thereto was a partner with the Vancouver law firm of Ladner Downs (now Borden Ladner Gervais) where his practice focused on corporate, securities and international mining transactions law. Frydenlund holds a bachelor’s degree in business and economics from Simon Fraser University, a master’s degree in economics and finance from the University of Chicago and a law degree from the University of Toronto.

Curtis H. Moore, Vice President of Marketing and Corporate Development
Curtis H. Moore is the vice president of Marketing and Corporate Development for Energy Fuels. He oversees product marketing for Energy Fuels, and is closely involved in mergers & acquisitions, investor relations, public relations, and corporate legal. He has been with Energy Fuels for over 12 years, holding various roles of increasing responsibility. Prior to joining Energy Fuels, Moore worked in multi-family real estate development, government relations and public affairs, production homebuilding, and private law practice. Moore is a licensed attorney in the State of Colorado. He holds Juris Doctor and MBA degrees from the University of Colorado at Boulder, and a Bachelor of Arts dual degree in Economics-Government from Claremont McKenna College in Claremont, California.

Energy Fuels Inc. (UUUU), closed Monday's trading session at $7.11, up 2.0086%, on 1,561,856 volume. The average volume for the last 3 months is 1,014 and the stock's 52-week low/high is $4.69/$11.00.

Recent News

QSAM Biosciences Inc. (OTCQB: QSAM)

The QualityStocks Daily Newsletter would like to spotlight QSAM Biosciences Inc. (OTCQB: QSAM).

QSAM Biosciences (OTCQB: QSAM) is developing next-generation therapeutic radiopharmaceuticals,including Samarium-153-DOTMP (CycloSam(R)), for the treatment ofbone cancer and related diseases and conditions. The company todayannounced that it has been invited to present at the EmergingGrowth Conference at 10:15 a.m. ET on Wednesday, Jan. 25, 2023.Leading QSAM’s presentation will be the company’s CEO Douglas Baumand other executive officers, who may subsequently open the floorfor questions. Interested parties should visit https://ibn.fm/P2xIR to register to attend the conference and receive any updates. Anarchived webcast will be made available on EmergingGrowth.com and on the Emerging Growth YouTube channel for those unable to join the event live on the day of theconference.

To view the full press release, visit https://ibn.fm/I9B0U

QSAM Biosciences Inc. (OTCQB: QSAM) is a clinical stage biotechnology company focused on bringing to market targeted therapeutic radiopharmaceuticals. The company is committed to advancing the fight against cancer through the discovery, development and delivery of effective treatment options for adult and pediatric patients.

QSAM Biosciences was founded in 2020 by Executive Chairman Dr. C. Richard Piazza and CEO Douglas Baum. It is headquartered in Austin, Texas.

CycloSam®

CycloSam®, QSAM Biosciences’ initial technology, is a clinical-stage bone targeting radiopharmaceutical invented by world-renowned scientists at IsoTherapeutics Group LLC. By leveraging a patented, low specific activity form of Samarium-153 (resulting in far less undesirable europium impurity) and what management believes to be a superior chelating agent in DOTMP, CycloSam is designed to selectively target sites of high bone mineral turnover to deliver a prescribed tumor-killing dose of radiation to the bone tumor sites while minimizing radiation exposure to nearby healthy tissue. These parameters are currently being tested in an FDA-cleared clinical trial.

CycloSam® has been shown in laboratory testing to cause significantly less (30x less) buildup of long-lived radionuclidic impurities than prior FDA-approved drugs, which management believes will enable the ability to safely administer therapeutic doses via higher and multiple-dose regimens and effectively expand its potential clinical utility to therapeutic uses in areas of high unmet medical needs.

The indications for CycloSam® currently being evaluated by QSAM Biosciences include:

  • Metastatic Bone Cancers – On April 28, 2022, QSAM Biosciences announced that the first patient had commenced treatment in its clinical trial evaluating CycloSam in patients with metastatic bone cancer. As noted in the release, the study is a Phase 1 open-label, dose-escalation trial to evaluate the safety, tolerability, dosimetry, and preliminary efficacy of CycloSam®.
  • Pediatric Osteosarcoma/Ewing’s Sarcoma – On February 2, 2022, the company announced that the U.S. FDA has granted Rare Pediatric Disease Designation to CycloSam for the treatment of osteosarcoma. Combined with a previously granted orphan drug designation for osteosarcoma received in 2021, this milestone “may allow QSAM to potentially bring CycloSam® to market more rapidly through additional incentives and eligibilities,” according to CEO Douglas Baum.
  • Bone Marrow Ablation – In a 2020 single patient Investigational New Drug (IND) study, an investigator concluded that high-dose CycloSam® can be administered safely to ablate bone marrow in advance of a stem cell transplant with no apparent renal toxicity and no unexpected adverse events attributable to the drug.

QSAM Biosciences’ preclinical and clinical development pipeline is supported by a strong IP portfolio. The company has secured 14 patents across three distinct patent families spanning the U.S., Japan, Canada and the European Union.

Market Outlook

Through its ongoing development of CycloSam®, QSAM Biosciences is targeting multiple large and underserved market opportunities. According to the American Cancer Society, roughly 400,000 new cases of malignant bone metastasis are diagnosed annually in the U.S. alone. Additionally, QSAM will pursue indications for osteosarcoma and Ewing’s sarcoma that are the most common primary malignancies of bone tissues in children.

Despite this pressing need, the current standard of care for bone cancer is aggressive and suboptimal, leading to marginal success with significant side effects and poor long-term survival prognosis. As a result, QSAM Biosciences estimates a sizable market opportunity for its development pipeline.

  • Bone Metastasis has an estimated total addressable market of $20 billion in the U.S. based on total new cases and comparable drug pricing.
  • Osteosarcoma/Ewing’s Sarcoma have a total addressable market of roughly $125 million in the U.S. based on approximately 1,000 new cases in 2021.
  • The total addressable market for Bone Marrow Ablation is projected at $1 billion, with an estimated 32,000 procedures completed annually.

The company anticipates that the ability to administer CycloSam® for higher and multiple-dose regimens may expand its clinical utility for therapeutic uses in additional areas of high unmet medical needs.

Management Team

QSAM Biosciences is led by an experienced management team and board with an extensive record of FDA approvals, big pharma partnerships and M&A transactions.

Dr. C. Richard Piazza is the Executive Chairman of QSAM Biosciences. Since 2017, he has also served as President and CEO of IGL Pharma Inc., the licensor of CycloSam®, and as a consultant to IsoTherapeutics Group LLC, the inventors of the technology. Dr. Piazza also currently serves on the board of directors of NovaScan LLC, a privately held cancer detection and diagnostics company. He has more than 48 years of health care experience in both medical devices and pharmaceutical/biotech and has led several technology companies to market success, including numerous FDA approvals in both sectors. Dr. Piazza obtained a BS in Economics and a BS in Speech Pathology from the State University of New York and an MA & PhD in Economics from the University of Buffalo and Leeds University.

Douglas R. Baum is the company’s CEO and Director. He brings to QSAM Biosciences over 30 years of experience in the bioscience and biotech industries, including development, FDA/EMA approval and commercialization of multiple drugs and medical devices. Mr. Baum has overseen 15 product approvals through the FDA and EMA and raised over $85 million in capital to fund breakthrough technologies. From 2017 to 2020, he consulted with multiple medical schools and biotech and pharmaceutical companies, and, from 2012 to 2017, he served as President, Chief Executive Officer and Director of Xeris Pharmaceuticals Inc. Mr. Baum holds a Master of Science in Technology Commercialization and a BBA in International Business and Marketing from the University of Texas.

Adam King is the CFO of QSAM Biosciences. He is also the Founder and CEO of King Consulting Group, where he provides a range of financial and reporting services for clients. Before founding King Consulting Group in January 2021, Mr. King was the CFO for Netsertive, a venture-backed digital marketing company. From 2016 to 2018, he was the Office Managing Audit Director for BDO’s Greenville, South Carolina, office, in addition to serving as Audit Director in Raleigh, North Carolina, and Boston, Massachusetts. While at BDO, Mr. King worked with various clients, from tech and life science start-ups to billion-dollar publicly traded companies. He holds a Bachelor of Science in Accounting from Elon University and is a CPA in Raleigh, North Carolina.

QSAM Biosciences Inc. (OTCQB: QSAM), closed Monday's trading session at $5, up 0.200401%, on 1,014 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $11.00/$.

Recent News

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV)

The QualityStocks Daily Newsletter would like to spotlight BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV).

Current monoclonal antibody therapies less effective againstemerging COVID-19 variants

BiondVax is developing an inhaled nanosized antibody (NanoAb)therapy for COVID-19 with human clinical Phase 1/2a resultsanticipated in 2023

The global monoclonal antibodies market was valued at $185.5billion in 2021 and is projected to grow at a CAGR of 11.3% due tothe rising prevalence of chronic diseases and demand for biologics

The biologics market size was valued at $366.5 billion in 2021 andis expected to reach $719.94 billion by 2030

According to a new study, new COVID-19 subvariants have becomedominant in recent months, rendering some current vaccines andtreatments less effective, which could results in a surge ofbreakthrough infections. To date, the BQ.1, BQ.1.1, XBB, and XBB.1omicron subvariants are the most immune evasive variants ofCOVID-19 – causing 72% of new infections in the United States,according to data from the Centers for Disease Control andPrevention (https://ibn.fm/0n3vY).BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing andcommercializing innovative immunotherapeutic products primarily forthe treatment of infectious and autoimmune diseases, todayannounced additional results in a preclinical proof-of-conceptstudy of its innovative inhaled NanoAb COVID-19 drug. According tothe update, the study used an industry-standard animal model tocompare weight loss in two groups of hamsters. Hamstersadministered a mid-sized 0.66mg dose of the NanoAb three hoursprior to infection experienced no significant weight loss over thesix-day trial, whereas the untreated control group’s weightdeclined 12% on average, a highly statistically significantdifference (p<0.0005). “We continue to be thrilled with theresults of this ongoing trial,” said BiondVax’s CEO Amir Reichman.“There is strong market demand for COVID prophylactics as evidencedby AstraZeneca’s reported Q1 through Q3 2022 EVUSHELD revenues of$1.5 billion*. EVUSHELD is currently the only prophylactic COVIDmedication with FDA approval, under emergency use authorization.Our inhaled NanoAb is designed to be self-administered at the timeof choosing to generate rapid protection from COVID illness. Incontrast, EVUSHELD must be administered via two separateconsecutive intramuscular (‘IM’) injections in a health caresetting, and the FDA has confirmed it does not effectivelyneutralize recent Omicron variants of concern.** Data from ourtrial indicate that our NanoAb may effectively serve as both atherapeutic and protective prophylactic drug, which furtherenhances its value proposition.” To view the full press release,visit https://ibn.fm/JQ1c9

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses.

In collaboration with the prestigious Max Planck Institute for Multidisciplinary Sciences (MPG) and the University Medical Center Göttingen (UMG), both in Germany, BiondVax is developing a pipeline of innovative nanosized antibody (NanoAb) therapies addressing diseases underserved by current treatments and with large and growing markets, such as COVID-19, asthma and psoriasis.

NanoAbs, also known as VHH-antibodies or Nanobodies, are alpaca-derived nanosized antibodies that exhibit multiple significant competitive advantages over existing antibody therapies, including stability at high temperatures, superior binding affinity, more effective and convenient routes of administration and efficient production. BiondVax is uniquely positioned to advance nanosized antibody innovation from R&D through commercialization.

The company’s highly experienced and successful pharmaceutical industry leadership team includes former senior executives from Novartis, GSK and Bristol-Myers Squibb.

Since its founding, BiondVax has executed eight clinical trials, including a seven-country, 12,400-participant Phase 3 trial of a prior influenza vaccine candidate, and it built, owns and operates a 20,000 sq. ft. state-of-the-art GMP biologics manufacturing facility housing its laboratories, production facilities and offices.

Lead Candidate: Inhaled COVID-19 NanoAb

In December 2021, BiondVax signed definitive agreements with the Max Planck Society – parent organization of the Max Planck Institute for Multidisciplinary Sciences– and the UMG to enter a strategic collaboration for the development and commercialization of innovative COVID-19 NanoAbs.

The company is planning a rapid development path that leverages its expertise and capabilities in biological drug development and manufacturing. BiondVax anticipates preclinical proof-of-concept results for an inhaled COVID-19 NanoAb by the end of 2022, with initial Phase 1/2a human clinical trial results expected in 2023.

The intended inhaled mechanism of delivery of BiondVax’s COVID-19 NanoAb formulation may serve as a significant differentiator when compared to approved monoclonal antibodies, which are injected. Inhaled delivery has shown to be cheaper, more convenient and likely safer for patients and providers.

NanoAb Pipeline: Psoriasis, Asthma and More

The COVID-19 NanoAb development agreement is part of a broader five-year research collaboration agreement signed in March 2022 covering discovery, development and commercialization of NanoAbs for several other disease indications with large market medical needs, including asthma, psoriasis, macular degeneration and psoriatic arthritis.

BiondVax has an exclusive worldwide license for development and commercialization of COVID-19 NanoAbs and exclusive options for similar worldwide licenses for NanoAbs for the above mentioned additional large market disorders currently underserved by approved therapeutic antibodies.

Academic research teams from MPG and UMG have verified strong affinity by the new NanoAbs to their biological target molecules and high thermostability. They have also demonstrated strong neutralization by several NanoAb candidates of their respective target molecules. Neutralization studies of the other NanoAbs are expected to begin later in 2022.

Based on the promising results, BiondVax will focus development efforts beginning with the following NanoAbs:

  • NanoAbs targeting IL-17 as drug candidates for the potential treatment of psoriasis and psoriatic arthritis
  • NanoAbs targeting IL-13 and NanoAbs targeting TSLP as drug candidates for the potential treatment of asthma

These are conditions for which the antibody target is validated by existing treatments and the mechanism of action is well understood. Both represent large medical needs and growing markets. BiondVax anticipates preclinical proof-of-concept for at least one of these NanoAbs in 2023. This is in addition to the aforementioned human clinical Phase 1/2a for the inhaled COVID-19 NanoAb therapy, which is also anticipated in 2023.

Market Opportunity

COVID-19 treatment, target of the company’s lead NanoAb therapy candidate, had an estimated market size of $22 billion in 2021.

Future BiondVax drug candidates will target conditions with large markets growing at attractive CAGRs.

The global asthma treatment market was valued at $18.08 billion in 2019 and is projected to reach $26.01 billion by 2027, exhibiting a CAGR of 4.5% during the forecast period, according to Fortune Business Insights. The research firm predicts that the global psoriasis treatment market will grow from $26.37 billion in 2022 to $47.24 billion by 2029, exhibiting a CAGR of 8.7% over the forecast period.

Management Team

Amir Reichman is BiondVax’s CEO. He previously was Head of Global Vaccines Engineering Core Technologies at GSK Vaccines in Belgium. Prior to that, he held leadership roles at Novartis Vaccines’ Global Vaccines Supply Chain Management organization. He was the first employee of NeuroDerm Ltd., a company focused on transdermal drug delivery, and served as Chief Engineer and Senior Scientist until his departure in 2009. He earned a M.Sc. in Biotechnology Engineering from Ben-Gurion University and an MBA in Finance and Health Care Management from the University of Pennsylvania’s Wharton School.

Tamar Ben-Yedidia, Ph.D., is Chief Science Officer at BiondVax. She has more than 30 years of experience in immunology, with specific expertise in the development of vaccines. She began her career with Biotechnology General Ltd., working on development of a recombinant Hepatitis-B vaccine. She later joined the Weizmann Institute of Science, working on the design of a peptide-based vaccine against several pathogens. She is widely published, with numerous refereed articles and invited reviews in various scientific journals. She received her Ph.D. from the Weizmann Institute.

Elad Mark is COO at BiondVax. He has over 15 years of biotechnology industry experience encompassing diverse project stages including feasibility studies, conceptual and detailed design, commissioning, qualification and process validation. Prior to joining BiondVax, he led Novartis’s $800 million investment in a biologics facility in Singapore. With Biopharmax and Antero, both global pharmaceutical engineering companies, he successfully led projects in Israel, China and Singapore. He holds a BSc. in Engineering from the Afeka Tel Aviv Academic College of Engineering and an MBA from the Open University of Israel.

Uri Ben-Or is CFO at BiondVax. He has served as CFO with public life science companies traded on the TASE, OTC and Nasdaq. Ben-Or provides his services to BiondVax through CFO Direct, a company he founded and for which he serves as CEO. He served as the VP of Finance of Glycominds, a leading biotechnology company, and as CFO of a spin-off from Telrad Networks. He also served as a Corporate Controller at Menorah Capital Markets and as an Auditor at PWC. He holds a B.A. in Business from the College of Administration, an MBA from Bar-Ilan University, and is a CPA.

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), closed Monday's trading session at $2.77, up 0.727273%, on 716,861 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $2.37/$22.90.

Recent News

Lexaria Bioscience Corp. (NASDAQ: LEXX)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (NASDAQ: LEXX).

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has a newstrategic advisor. The company announced that Julian Gangolli, theformer president of GW Pharmaceuticals USA, has joined Lexaria as astrategic advisor. During his time at GW Pharmaceuticals, Gangollimanaged US Food and Drug Administration approval of Epidiolex(R),the only pure cannabidiol (“CBD”) drug ever approved by the agency;he also oversaw the commercialization of the drug in the UnitedStates, which ultimately led to Jazz Pharmaceuticals acquiring GWPharmaceuticals in a $7.2 billion transaction. In addition to hiswork at GW Pharmaceuticals, Gangolli served as North Americanpresident of Allergan and a member of its executive managementteam, which guided the sale of Allergan to Actavis. In theannouncement, Gangolli noted that Lexaria has become an establishedforce in the field of improved drug delivery, and he hopes toassist the company in its commercial development of DehydraTECH.“As we intensify our focus during 2023 on commercial execution ofour robust DehydraTECH technology portfolio, I am very pleased towelcome Julian with his extensive pharmaceutical experience, to thebroadening Lexaria team,” said Lexaria CEO Chris Bunka in the pressrelease.

To view the full press release, visit https://ibn.fm/v6XaM

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator in drug delivery platforms. The company’s patented technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules. DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.

DehydraTECH is covered by 21 issued and more than 50 pending patents in over 40 countries around the world. Lexaria’s first patent was issued by the U.S. Patent and Trademark Office in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.

Lexaria has a collaborative research agreement with the National Research Council (NRC), the Canadian government’s premier research and technology organization. The company has filed for patent protection for specific delivery of nicotine, vitamins, NSAIDs, testosterone, estrogen, cannabinoids, terpenes, PDE5 inhibitors (with brand names like Viagra), tobacco and more.

Lexaria began developing DehydraTECH in 2014 and has since continued to strengthen and broaden the technology. The company has no plans to create or sell Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats.

The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products, and for use in industries that produce cannabinoid beverages, edibles and oral products.

DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions.

DehydraTECH Technology

Lexaria’s DehydraTECH is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. DehydraTECH increases their effectiveness and improves the way active pharmaceutical ingredients enter the bloodstream. The major benefits to a subject ingesting a DehydraTECH-enabled drug or consumer product can be summarized by the following:

  • Speeds up delivery – the effects of the product are felt by the subject in just minutes.
  • Increases bioavailability – the technology is much more effective at delivering a drug or product into the bloodstream.
  • Increases brain absorption – animal testing suggests significant improvement in the quantity of drug delivered across the blood-brain barrier.
  • Improves drug potency – more of the ingested product is made available to the body, so lower doses are required to achieve the desired effect.
  • Reduces drug administration cost – lower doses mean lower overall drug costs.
  • Masks unwanted taste – the technology eliminates or reduces the need for sweeteners.

Lexaria has demonstrated in animal studies a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,900 percent, initiating additional new patent applications and opening possibilities for improved drug delivery.

Since 2016, DehydraTECH has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to 10 times, reduce time of onset from one to two hours to just minutes, and mask unwanted tastes. The technology is to be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and nicotine.

Market Outlook

Lexaria’s ongoing research and development efforts are mainly focused on development of product candidates across several key segments:

  • Oral Cannabinoids – a market estimated to be worth $18.4 billion in 2021 and expected to reach $46.2 billion by 2025.
  • Antivirals – an estimated $52.1 billion market in 2021 that’s expected to grow to $66.7 billion by 2025.
  • Oral Mucosal Nicotine – smokeless tobacco products, a $13.6 billion market in 2018, is forecast to grow at 7.2 percent annually through 2025.
  • Human Hormones – estrogen and testosterone replacement therapies represented a $21.9 billion market in 2019, with a forecast CAGR of 7.7 percent through 2027.
  • Ibuprofen and Naproxen – NSAID sales totaled $15.6 billion globally in 2019 and are projected to reach $24.4 billion by 2027.
  • Vitamin D3 – the global market size was $1.1 billion in 2021, growing at 7 percent per year and expected to reach $1.7 billion in 2026.

Management Team

Chris Bunka is Chairman and CEO of Lexaria Bioscience Corp. He is a serial entrepreneur who has been involved in several private and public companies since the late 1980s. He has extensive experience in the capital markets, corporate governance, mergers and acquisitions, as well as corporate finance. He is named as an inventor on multiple patent innovations.

John Docherty, M.Sc., is the President of Lexaria. He is a pharmacologist and toxicologist, and a specialist in the development of drug delivery technologies. He is the former president and COO of Helix BioPharma Corp. (TSX: HBP). He is named as an inventor on multiple issued and pending patents.

Greg Downey is Lexaria’s CFO. He has more than 35 years of diverse financial experience in the mining, oil and gas, manufacturing, and construction industries, and in the public sector. He served for eight years as CFO for several public companies and has provided business advisory and financial accounting services to many large organizations.

Gregg Smith is a strategic advisor to Lexaria. He is a founder and private investor with Evolution VC Partners. He is a member of the Sand Hill Angels and held previous investment banking roles with Cowen and Company and Bank of America Merrill Lynch.

Dr. Philip Ainslie serves as a scientific and medical advisor to Lexaria. He is co-director for the Centre for Heart, Lung and Vascular Health, Canada. He is also Research Chair in Cerebrovascular Physiology and Professor at the School of Health and Exercise Sciences, Faculty of Health and Social Development at the University of British Columbia.

Lexaria Bioscience Corp. (LEXX), closed Monday's trading session at $2.75, up 1.1029%, on 23,661 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $1.80/$4.83.

Recent News

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

The American Cancer Society Journals estimates that there will be 1.9 million additional cancer diagnoses and 609,820 millioncancer deaths this year. The deadly disease affects tens of millions of peopleglobally and causes millions of deaths across the world every year. Consequently, researchers are always looking for saferand more effective ways of preventing, detecting, and treating allkinds of cancers. Researchers from India’s Tata Memorial Center have found evidence showing that nutraceuticals, which are foodextracts that have health benefits on top of their nutritionalvalue, may have promise in the prevention and treatment of cancer.The fight against cancer is being waged on different fronts, andwhen those efforts of actors like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) and other teams yield the expected results, patients stand ahigher chance to survive their diagnoses and enjoy better qualitylives.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (http://nnw.fm/eDUjp).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Monday's trading session at $2.32, up 4.9774%, on 35,745 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $2.05/$20.10.

Recent News

Freight Technologies Inc. (NASDAQ: FRGT)

The QualityStocks Daily Newsletter would like to spotlight Freight Technologies Inc. (NASDAQ: FRGT).

Freight Technologies (NASDAQ: FRGT), a technology company whose custom-developed Fr8App, anindustry-leading freight-matching platform powered by AI andmachine-learning, offers a real-time portal for B2B cross-bordershipping and domestic shipping within the USMCA region, hasannounced a new, automated and effortless carrier onboardingprocess. The new process, states the company, makes it even easierqualified carriers to sign up and move loads with Fr8App. Theannouncement noted that qualified carriers who sign up on theFr8App platform, can approved and unlock all the platform optionsin only minutes; users simply follow step-by-step instructions thatare provided. The new streamlined process eliminates the tediousand sometimes frustrating requirement of completing hard-copyforms. “By Introducing this new automated onboarding process forour carrier partners, we affirm our ongoing commitment to simplifyand digitalize the transportation industry,” said Fr8App CEO JavierSelgas in the press release. “Our goal is to make the process ofjoining our platform as simple and efficient as possible, socarriers can focus on what they do best: moving loads and growingtheir business. Following the recent redesign of our app'snavigation tools, we are introducing an updated system that isresponsive to our customer requests and makes it incredibly simplefor eligible carriers to join and transport loads with Fr8App.”

To view the full press release, visit https://ibn.fm/4tmh8

Freight Technologies Inc. (NASDAQ: FRGT) (“Fr8Tech”) is a technology company developing solutions to optimize and automate the supply chain process, providing a platform for B2B cross-border shipping in the NAFTA region. The company’s mission is to revolutionize cross-border shipping by providing carriers with increased growth opportunities and shippers with flexibility, visibility and simplicity for the once-complex process of international over-the-road shipping.

Freight Technologies, formerly known as Hudson Capital Inc., assumed its current name and ticker symbol on May 27, 2022. Its primary operating subsidiary and its marketplace are known as Fr8App, and it conducts operations throughout North America under the names of Fr8App and/or Freight App. The company is headquartered in Houston, Texas, with multiple locations across the U.S. and Mexico.

The Fr8Tech Solutions Suite

Fr8Tech leverages artificial intelligence to provide cloud-based platforms aimed at automating the over-the-road transportation process, effectively reducing human touch points and expediting load booking times. The company’s suite of solutions includes:

  • Fr8app – A B2B marketplace powered by AI and Machine Learning offering a real-time broker portal to connect shippers with qualified carriers
  • Fr8Radar – A tracking solution providing shippers and carriers real-time locational data via Fr8app’s mobile solution or through integration with third-party GPS alternatives
  • Fr8TMS – A transportation management system designed to help shippers manage their freight and all of the documents involved in shipping transactions, including invoices, customs documents, confirmation rates and proof of deliveries
  • Fr8FMS – A fleet management system allowing transportation companies to better manage their fleets, reduce operational costs and provide better service to their customers
  • Fr8Data – A data solution offering real-time dashboards and reports to shippers and carriers in an effort to increase visibility and control while supporting better business decisions
  • Fr8Fleet – A platform that provides private fleet management, enabling large corporate shippers to purchase dedicated capacity secured by Fr8app in exchange for a fixed fee

Commitment to the Environment

Through its core focus on technology, Fr8Tech seeks to reduce the carbon footprint of the logistics industry. Its solutions aim to minimize empty miles for transportation firms and reduce overall paper consumption.

Fr8University

Fr8University is an educational program offering classroom and on-the-job training for Fr8Tech team members. Through the program, employees learn in-depth business fundamentals and applications along the truckload freight industry value chain.

Led by corporate educator Mario Mena, Fr8University is designed as an investment in the company’s human capital, providing an opportunity to communicate Fr8Tech’s corporate culture while accelerating operational growth.

Market Outlook

Fr8Tech’s established foothold in Mexico is key to its current efforts to promote sustainable growth in the cross-border shipping industry. Ongoing disruption in U.S.-Chinese trade relations have strengthened Mexico’s status as the largest trading partner of the U.S., with cross-border annual freight spending estimated at $385 billion according to data from the U.S. Department of Transportation. Annual domestic shipping in Mexico is estimated at $34 billion, while annual domestic shipping in the U.S. is estimated to total $732 billion.

Despite the size of this industry, fragmentation and inefficiencies prevail in the space. Thousands of legacy brokers, tens of thousands of shippers and hundreds of thousands of carriers still rely on outdated systems to arrange transport, spending hours on the phone negotiating pricing, waiting days to find trucks and drivers, preparing and printing forms, and operating without tracking or visibility. Add in cross-border complexity relating to customs and additional paperwork, and you have an industry ripe for technological disruption.

Fr8Tech’s recent revenue growth trends have highlighted the company’s efforts to capitalize on this opportunity. In 2021, Fr8Tech achieved revenues of $21.5 million, marking a year-over-year increase of 134%. The company issued revenue guidance for fiscal 2022 of $40 million in a February 9, 2022, press release, which would account for a further 86% year-over-year increase.

Management Team

Javier Selgas is CEO and a Director of Freight Technologies Inc. and Freight App Inc. He brings to the company over 15 years of experience developing technology and digital marketing strategies, including serving as Country Manager for Osigu, Spain, and as head of AJEgroup’s IT division for the Asia-Pacific region. Prior to joining Fr8Tech, Mr. Selgas founded digital marketing agency Lanzadera Online. He has also served as an IT consultant to major corporations, including Endesa and Ibermatica.

Mike Flinker is President of Fr8Tech. He has over four decades of experience in the transportation industry, with 30+ years focused on cross-border logistics. Prior to joining Fr8Tech, Mr. Flinker founded FLS Transportation, the largest cross-border logistics company in Canada. He also previously held positions with Clarke Transport Inc., Canadian Pacific and Reimer Express Inc. (a division of Roadway Express).

Paul Freudenthaler is the company’s CFO and Secretary to the company Board. He has over 30 years of financial expertise, having previously served as CFO for several leading companies across multiple countries, including Macquarie in Mexico, Old Mutual in Latin America and Ascentium Capital in the U.S. Mr. Freudenthaler’s experience include leadership roles from which he guided IPOs and M&A transactions.

Luisa Lopez is COO of Fr8Tech. She brings to the company 25+ years of management experience in logistics, supply chain, operations and customer service. Ms. Lopez previously served as a Director of Landstar, where she was responsible for commercial and client development strategies in the Mexican market. Additionally, she managed more than 2,000 transport units specialized in staff and school mobility while with Traxion in Mexico.

Freight Technologies Inc. (NASDAQ: FRGT), closed Monday's trading session at $0.315, up 13.1872%, on 2,558,456 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.1799/$7.766.

Recent News

Flora Growth Corp. (NASDAQ: FLGC)

The QualityStocks Daily Newsletter would like to spotlight Flora Growth Corp. (NASDAQ: FLGC).

Research from the University of Colorado, which was recently published inthe publication “Psychological Medicine,” found that recreationaldecriminalization was linked to increased marijuana use and reduced alcohol use disorder (AUD) symptoms but wasn’t linked to other maladaptations. The researchersadvised, nevertheless, that this information is difficult toassess and deserves exploratory research in future studies.Although their results show that marijuana consumption isnot risky, the researchers could not pinpoint major variations inthese bad consequences as effects of legalizing marijuana. Theyfound that inasmuch as there was a negligible difference in averagealcohol intake, individuals living in areas where cannabis waslegal seemed more unlikely to get injured when they were underalcohol influence versus their twins who resided in regions wherecannabis was still prohibited. Additionally, in a study published in “PLOS One” last year, researchers from Michigan State University suggestedthat in states where marijuana is legal, cannabis sales volumescould be preceded by the increasing incidences of marijuana onsetsfor older individuals but not for barely legal individuals whocannot purchase recreational cannabis in a retail outlet. As moreof these studies document the wide-ranging benefits of marijuanaand its constituent compounds, industry players such as Flora Growth Corp. (NASDAQ: FLGC) will gradually be perceived a lot more fondly than prohibitionistscurrently give them credit for.

Flora Growth Corp. (NASDAQ: FLGC) is an internationally focused cannabis brand builder that leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions, including cosmetics, hemp textiles, and food and beverage. Flora Growth operates one of the largest outdoor cultivation facilities in the world with an aim of marketing a higher-quality premium product at below-market prices. By prioritizing natural ingredients and value-chain sustainability across its portfolio, the company creates premium products that help consumers restore and thrive.

Flora Growth completed the first traditional cannabis IPO on Nasdaq in May 2021. Although currently headquartered in Toronto, Ontario, with plans to relocate its head office to Miami, Florida, the company’s base of operations is in Colombia, where it has built an extensive distribution network that includes Colombia’s largest distributors.

Currently, Flora Growth is organically growing market share for its existing brand portfolio (pharmaceuticals, textiles, cosmetics, and food & beverage) while seeking revenue-generating acquisitions that offer an accretive distribution network to amplify revenue growth.

Existing Brand & Product Portfolio

Flora Growth’s portfolio spans a number of verticals – each with a thoughtful brand designed to resonate with its intended end consumer. In line with the company’s mission, each brand prioritizes natural ingredients and value-chain sustainability.

Flora Lab S.A.S

Flora Lab is the company’s GMP certified manufacturing and R&D center focused on producing pharmaceuticals, cosmetics, and nutraceuticals for domestic and international markets. Its offerings include product lines that are private label, white-label, and custom formulas.

Through Flora Lab, Flora Growth has relationships with 1,500+ distribution channels, manufactures 63+ OTC products registered with INVIMA (Colombia National Food and Drug Surveillance Institute), and holds multiple GMP certifications enabling international export in an effort to leverage Flora Lab’s capacity to produce a wide range of CBD-infused products.

Flora Beauty

Flora Beauty is the company’s CBD beauty and cosmetics division founded by fashion and beauty industry icon Paulina Vega. Its current offerings include two CBD skincare brands targeting the U.S. and Latin American markets – MIND NATURALS and AWE. These lines exemplify Flora Growth’s socially conscious approach to business.

Currently, Flora Beauty products are offered globally through e-commerce, as well as through Falabella’s 111 retail locations across Latin America. The company is in negotiations with major department stores to launch the line in the U.S. and is also exploring opportunities in the U.K. and other European markets.

KASA Wholefoods

KASA Wholefoods is a Colombian manufacturer of food and beverages leveraging responsibly sourced exotic fruits from the Amazon. KASA has a $10 million+ distribution agreement with Tropi, Colombia’s largest food distributor, which has 130,000+ distribution points across the country.

Mambe, KASA’s leading brand, is already offered through over 980 distribution points across Colombia. Flora Growth expects this network to grow to over 1,200 distribution points in 2021, including one of Colombia’s largest coffee chains, Tostao Café & Pan.

Hemp Textiles & Co.

Through its Hemp Textiles division, Flora Growth intends to utilize its large land package and cultivation infrastructure to capture market share in the rapidly growing hemp industrials segment.

The company’s first brand through this division, Stardog Loungewear, offers a line of comfortable loungewear made from natural, organic materials. Stardog has been distributing globally through e-commerce and brick and mortar channels in Bogota since fall 2020, and the company intends to open U.S. brick and mortar locations in 2021.

Accretive M&A

Flora Growth is targeting transactions to complete the supply chain via key infrastructure to enhance its global distribution with the aim to compete on low-cost, high-quality inputs paired with premium brands that create business lines with robust margins.

To date, Flora has announced two major transactions.

Koch & Gsell (Acquisition)

  • Amplify CPG portfolio’s revenue growth through leading brand, Heimat, currently with TTM revenues of $7.6 million.
  • Leverage Koch &Gsell’s distribution network of 2,500+ stores to introduce Flora to the Swiss, European and Asian markets.
  • Bring patented hemp cigarette manufacturing technology into new markets utilizing Flora’s high-quality cannabis.

Hoshi International (Investment)

  • Equity Investment of €2 million into Hoshi to establish Flora as a preferred supplier to two EU processing facilities.
  • Opens gateway for Flora Growth’s cannabis through international distribution agreements in the EU and U.K.
  • Hoshi’s experienced team and increased access to the EU cannabis market to serve as a catalyst for revenue growth.

Cultivation

Key to Flora Growth’s expansion efforts is its cultivation strategy. The company’s Cosechemos farm, located in Bucaramanga, Colombia, is currently licensed to cultivate 247 acres of cannabis. Through three successful pilot crop plantings, the location has demonstrated a production cost of just $0.06/gram. For comparison, the average cost of North American cannabis (based on 2019 figures from Aphria, Tilray, Sundial, and Aurora) equates to roughly $1.89/gram.
Flora Growth is uniquely positioned to capitalize on Colombia’s favorable growing conditions, low-cost infrastructure, and affordable local workforce as it looks to ramp up its cultivation efforts moving forward.

Leadership Team

Bernard Wilson is the Chairman of Flora Growth. A senior financial professional, Dr. Wilson is the former Vice-Chairman of PricewaterhouseCoopers LLP and is the Chairman of the Founders Board of the Institute of Corporate Directors. He has also served as Chairman of the Canadian Chamber of Commerce; Chairman of the International Chamber of Commerce – Canada; and Member of the Canada/U.S. Trade Committee. Dr. Wilson draws on this experience to ensure Flora Growth adheres to effective corporate governance practices.

Luis Merchan is the company’s President and CEO. He is a proven executive with over a decade of experience in enterprise sales management, corporate strategy, merchandising and expense management, and customer experience. Mr. Merchan previously served as Macy’s Inc.’s Vice President of Workforce Strategy and Operations, where he managed the enterprise’s multi-billion-dollar P&L expense line for the entire 540 store portfolio. Throughout his tenure at Macy’s, he led various sales and marketing initiatives, including the B2B corporate sales team that was responsible for $160 million in annual revenue. Mr. Merchan obtained his Bachelor of Industrial Engineering from Pontifical Xaverian University in Bogota, Colombia, and his MBA from McNeese State University. He also holds a Graduate Certificate in Marketing Management from Harvard.

Juan Manuel Galan is a Strategic Advisor to the Flora Growth management team. Mr. Galan currently serves as a senior consultant to The World Bank. He is a politician and former senator of Colombia, serving three terms from 2006 to 2018 as a member of the Colombian Liberal Party. He is also a former professor at the University of Rosario and holds more than 20 years of journalistic, academic, governmental and parliamentary experience. During his time as a senator, Mr. Galan was a key leader, with 29 bills and 27 debates on political control, and 17 laws to his name. The most relevant of those laws was authoring the medical cannabis law that resulted in the legalization of medical cannabis in Colombia.

Stan Bharti is a Director of Flora Growth. Mr. Bharti currently serves as Executive Chairman of Forbes & Manhattan. He has more than 30 years of professional experience in business, finance, markets, operations and more, with a focus on the resource and technology sectors. To date, Mr. Bharti has amassed over $3 billion worth of investment capital for the companies with which he has worked and their shareholders. He is a Professional Mining Engineer and holds a master’s degree in engineering from Moscow, Russia, and University of London, England.

Javier Franco is the company’s VP of Agriculture. Mr. Franco is a master horticulturist with more than 25 years of experience in the design, implementation, and management of cultivation and propagation facilities of more than 30 species of cut flowers in Latin America. He completed his agricultural studies at Zamorano University in Honduras and later at an International Exchange Program at Ohio State University. Mr. Franco has directed technical, commercial, and research groups in the cut flower, fruit and vegetable markets in Latin America and has participated in the commercial development of new technologies applied in agribusiness. He has also led the agri-management of organic crops and certifications of Good Agricultural Practices.

Flora Growth Corp. (FLGC), closed Monday's trading session at $0.2755, up 5.9615%, on 2,498,707 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.1913/$2.38.

Recent News

Data443 Risk Mitigation Inc. (OTC: ATDS)

The QualityStocks Daily Newsletter would like to spotlight Data443 Risk Mitigation Inc. (OTC: ATDS).

In November 2018, Marriott suffered the loss of personal data foralmost 383 million guests, highlighting the pitfalls and risksattached to businesses boasting an online profile

Gartner revealed that 30% of enterprises would employ data securityplatforms by 2024, up from a mere 5% in 2019

Data443 caters to the growing need for data discovery, governance,and protection services through its extensive and growing productsuite – with services ranging from the data archiving and transferthrough to ransomware recovery

The company recently embarked on the next leg of its growthtrajectory, recently raising over $1.5M with proceeds set to bedevoted towards additional sales and marketing recruitment as wellas the uplisting of the company on to the Nasdaq exchange

Data443 also updated the market on the coveted VB100 certificationwhich was recently awarded to its flagship Data443(R) AntivirusProtection Manager(TM)

In November 2018, hotel chain Marriott saw its worst fearsrealized; a massive data breach was detected within its systemswith hackers stealing data belonging to as many as 383 millionguests. Nearly four years in its gestation, the hack was reportedlyalleged to have stolen a broad array of data including credit cardand passport numbers, birth dates, phone numbers as well as hotelarrival and departure dates (https://ibn.fm/u0Vq1). Data443 Risk Mitigation (OTC: ATDS), a data security and privacy software company, has centered itsmission around preventing the likes of the Marriott hack from everbeing repeated, stating its steadfast commitment towardsidentifying and protecting all sensitive data regardless oflocation, platform, or format.

Data443 Risk Mitigation Inc. (OTC: ATDS) is a data security and privacy software company for ALL THINGS DATA SECURITY™. The company is committed to organizing the world’s information by identifying and protecting all sensitive data regardless of location, platform or format.

Data443 provides software and services to enable secure data across devices and databases – at rest and in transit – locally, on a network, or in the cloud. With over 10,000 customers in more than 100 countries, Data443 provides a modern approach to data governance and security. The company’s framework helps customers prioritize risk, identify security gaps, and implement effective data protection and privacy management strategies.

Data443 derives revenue primarily from contracts for subscriptions to access its SaaS platforms, and ancillary services provided in connection with its subscription services. In today’s ever-changing environment with unique and complex requirements for data privacy, governance and hybrid workforces, every organization needs to know where all their data is, who has access to it and how sensitive it is. Data443 provides the tools needed to give companies control over their data processing activities, with capabilities for identifying, reporting and migrating or deleting sensitive data.

The company is headquartered in Research Triangle Park, North Carolina.

Products

Focused on data security with a privacy-forward methodology, the Data443 product suite delivers solutions designed to securely manage data and data privacy needs on-premises, in the cloud and in hybrid environments. Offerings include:

  • Data Identification Manager reduces risk by shining a light on dark data across cloud, on-premises and hybrid environments. From a centralized dashboard, Data Identification Manager provides the ability to automatically inventory all data repositories, classify and tag all data, and enable global search and discovery – all through an agentless deployment.
  • Data Placement Manager quickly and securely transfers sensitive data over any public or private network. Available as an HP Nonstop server-based application and for Windows, Linux or any public cloud provider, Data Placement Manager enables the scheduling, routing, formatting and transfer of business-critical data.
  • Data Archive Manager is an “all information, anywhere” archiving solution designed to handle and manage all types of privacy requests across cloud, on-premises and hybrid environments. With over 15 years operational history and hundreds of clients managing millions of mailboxes, the platform is purpose-built for information archiving, retention and privacy request management.
  • Data Hound™ is a data discovery, classification and capture toolset that enables organizations to perform quick scans, detailed reporting and subsequent data actions based on policy.
  • Ransomware Recovery Manager is the only industry solution that actively recovers the device, operating system and data with a simple reboot. Using patented, proven technology, the product produces 100% effectiveness for the whole device and datasets.
  • Access Control Manager provides user ID and passwordless access to quickly enable trust across an organization’s entire ecosystem. Its unique architecture allows it to leverage multiple distributed authoritative sources to understand and resolve a typical access request – with the ability to enable or deny the action on the fly.
  • Global Privacy Manager provides organizations one comprehensive view, for all privacy requirements, across all enterprise data, all at once. This unmatched visibility into an organization’s data assets ensures that all private and sensitive data can be identified and protected and that enterprises can obey all relevant privacy laws in any jurisdiction.
  • Sensitive Content Manager is a security-centric collaboration service designed to give organizations the tools needed for successful content sharing, collaboration and safe distribution with full enterprise management in mind. With a continuous sync feature, encrypted data is automatically downloaded and updated in real time – regardless of location – ensuring that users have the most accurate data available.

Market Outlook

A report from Allied Market Research estimates that the global data security market was worth about $19 billion in 2021 and is projected to reach a value of $54.23 billion by 2027. That represents a CAGR of more than 18% for the forecast period, making data security one of the hottest areas within IT.

Separately, Fortune Business Insights estimates the global data privacy software market is valued at $2.36 billion in 2022 and projects it will grow to $25.85 billion by 2029. That represents a CAGR of 40.8% over the forecast period.

Management Team

Jason Remillard is President, CEO and Founder of Data443. He is responsible for overseeing global expansion, management, execution and corporate development. With over 25 years in global enterprise and B2C software sales and marketing, he brings deep leadership and technical experience, having spent previous time at Fortune 500 companies such as Deutsche Bank, TD Bank, IBM & Merrill Lynch.

Greg McCraw is CFO at Data443. He has over 25 years of experience helping businesses strengthen their accounting and finance operations. He previously served as Vice President of Finance for a dental services organization active in acquisitions, and, prior to that, he was managing director of a boutique accounting and finance consulting firm advising Fortune 500 clients in pharmaceutical, financial services, and private equity sectors on how to execute on regulatory and compliance solutions.

Bennett Pursell is Data443’s Chief Technology Officer. He has over 20 years of experience in IT architecture, security governance and systems integration. Prior to his role at Data443, he served as Head of Technology Architecture at Moody’s Investor Services and was Vice President and Technical Architect of Cloud Computing at Deutsche Bank, along with a host of technical and project management roles dating back to 2006, after starting his career as a web developer with a few startups and running research labs.

Kirill Kashigin is Chief Software Architect at Data443. He leads the development and quality teams, and serves as technical adviser and subject matter expert, bringing vast technical knowledge on privacy management and data security. Formerly the CTO of FileFacets, he has nearly 20 years in development of high-performance systems and deployment.

Data443 Risk Mitigation Inc. (OTC: ATDS), closed Monday's trading session at $0.25, up 4.1667%, on 45,531 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.22/$6.99.

Recent News

McEwen Mining Inc. (NYSE: MUX) (TSX: MUX)

The QualityStocks Daily Newsletter would like to spotlight McEwen Mining Inc. (NYSE: MUX) (TSX: MUX).

McEwen Mining is an asset rich gold and silver producer with largeexposure to copper

McEwen Mining CEO Rob McEwen maintains a 17.3% ownership stake inMcEwen Mining with a cost base of roughly $220 million

McEwen Copper’s Los Azules project is one of the world’s largestand most economically robust underdeveloped copper projects

A proposed IPO of McEwen Copper, with its implied market cap of$258 million, could effectively turbocharge the balance sheet ofMcEwen Mining

McEwen Mining Inc. (NYSE: MUX) (TSX: MUX) is an asset rich diversified gold and silver producer in the Americas and has a large exposure to copper through its subsidiary, McEwen Copper, owner of the Los Azules copper deposit in Argentina, believed to be the 9th largest undeveloped copper resource in the world.

Led by a management team with a track record of success, MUX owns and operates mines in some of the most prolific gold producing regions in the Americas. In recent months, the company has undertaken strong actions to lower production costs and increase production across its portfolio of gold assets, driving some costs below the industry average. Gold and copper prices are forecast to enter a major uptrend over the next couple years. McEwen Mining is laying the groundwork to capitalize on this opportunity now.

Seldom is management so aligned with investors’ interests with a commitment to the company’s success. CEO Rob McEwen maintains a 17% ownership stake in McEwen Mining and a 15% ownership in McEwen Copper with a combined cost base of roughly $220 million. McEwen founded Goldcorp, where he took the company from a market capitalization of $50 million to over $8 billion, and that same vision led MUX to create McEwen Copper.

For McEwen Mining shareholders, the company’s 68% stake in McEwen Copper is expected to be a gamechanger, turbocharging MUX by creating the world’s next copper unicorn.

McEwen Copper

Most mined copper is currently used in infrastructure, with new critical demand emerging for use in the electrification of transportation and the global energy transformation. The price of copper rose from a low of about $2 per pound two years ago to over $4 per pound today, and strong demand is expected to continue to soar. A study by S&P Global, titled The Future of Copper: Will the Looming Supply Gap Short-circuit the Energy Transition?, projects global copper demand to nearly double over the next decade, from 25 million metric tons today to about 50 million metric tons by 2035. Based on current trends, S&P Global projects annual supply shortfalls to reach nearly 10 million metric tons in 2035.

McEwen Mining is a 68% shareholder in McEwen Copper, holder of a 100% interest in the Los Azules copper project in San Juan, Argentina, which was ranked the 9th largest undeveloped copper deposit in the world by Mining Intelligence (2022). Its current copper resources are estimated at 10.2 billion pounds at a grade of 0.48% Cu (Indicated category) and an additional 19.3 billion pounds at a grade of 0.33% Cu (Inferred category). McEwen Copper also owns a copper exploration project in Nevada, called Elder Creek.

In a 2017 Preliminary Economic Assessment (PEA), Los Azules was estimated to have a 36-year life, but indications are that the project could ultimately become an even larger mine, with a longer life, since in the assessment, only 55% of the known copper resources are to be mined. Numerous drill holes have shown strong copper mineralization extending below the PEA pit bottom. Its average annual production for its first 13 years was pegged at 415 million pounds of copper in the 2017 PEA – enough copper to supply 2.2 million electric vehicles per year.

In August 2022, McEwen Copper closed its non-brokered, private placement offering of $82 million, after securing a $25 million investment from mining giant Rio Tinto’s technology arm, Nuton LLC. This gives McEwen Copper an imputed value of $258 million, which would give McEwen Mining’s 68% interest a value of approximately $3.70/share. Additional value can be attributed to McEwen Mining’s 1.25% net smelter royalty on both the Los Azules and the Elder Creek projects.

“We completed an $82 million financing for McEwen Copper in a very tough equity market. Rio Tinto, the second largest mining company in the world, through its subsidiary Nuton, now owns 9.7% of McEwen Copper, a result of its investment of $25 million,” Rob McEwen stated in a news release. “Also, Nuton is testing the Los Azules copper mineralization to see if it can accelerate and increase copper recoveries. Another of Rio Tinto’s subsidiaries, Kennecott Exploration, signed an option to earn a 60% interest in McEwen Copper’s other copper project, Elder Creek, by spending $18 million on exploration.”

The Elder Creek project is prospective for porphyry copper and gold mineralization and is well situated in a district hosting several large copper and gold mines, including Marigold, Lone Tree and Phoenix. Kennecott Exploration will be the operator of the exploration program. McEwen Mining holds a 1.25% net smelter return (NSR) royalty on the Elder Creek property.

Following the capital raise, McEwen Copper is well-funded to advance its Los Azules Project. Publication of an updated PEA on the Los Azules copper project is planned for Q1 2023. In Q2, an IPO is planned, along with MUX completing a secondary offering, assuming no further private placements in the interim. MUX is strategically reducing its interest to increase its treasury, in order to reduce debt and fund the further development of its gold and silver mines.

McEwen Copper currently has an implied market cap of over $258 million, based on its most recently completed financing. However, when its Los Azules copper project is compared with other recent transactions and market valuations of copper projects in the same region, it appears very undervalued.

MUX’s management believes its ownership stake in McEwen Copper is not currently reflected in the share price of the company. In fact, it is management’s belief that the combined value of its 68% interest in McEwen Copper, plus its gold mines and portfolio of mineral royalties, represents a share value ranging from a low of $8 to a high of $30 per share. Rob McEwen provides a full breakdown of this valuation estimate in a news release detailing the company’s Q3 2022 results.

Gold & Silver Projects

The Fox Complex

McEwen Mining owns a 100% stake in the Fox Complex in the heart of a prolific gold district in Timmins, Canada.

“When MUX bought the Fox Complex, in late 2017, it was a distressed asset with a history of high operating cost/oz. While it has taken longer than I expected, the cost to produce an ounce of gold is significantly lower,” CEO Rob McEwen stated in a news release. “I am pleased to say that in Q3 our cash cost/oz at Fox fell to $774, our lowest since mid-2018. This is well below the industry average. With our mine operating much more efficiently, our next important area to improve at Fox is the process plant (mill). Specifically, we need to increase the throughput because our mine is now producing more ore than our mill can process. As a result, we have a large surface stockpile of ore equivalent to more than two months of production.”

This ore stockpile contains approximately 10,000 ounces of gold representing a potential source of $12 million in free cash flow.

Located in one of the most prolific gold production areas in the world, along the Destor-Porcupine Fault Zone within the Abitibi Greenstone Belt, the Fox Complex includes the Black Fox mine and Froome mine which together have, so far, produced in excess of 1,000,000 ounces of gold. Also, it includes the Grey Fox and Stock deposits that have an estimated additional 1,600,000 ounces in reserves and resources. The 2.7-billion-year-old Abitibi Greenstone Belt, formed by ancient volcanic activity, has proved to be one of the world’s richest and most abundant gold regions, boasting total gold content of over 300 million ounces.

Full year 2023 guidance for The Fox Complex puts production estimates at 45,000 GEOs, 28% of MUX’s total production.

The Gold Bar Mine

McEwen Mining owns a 100% stake in the Gold Bar mine located in an area well known for gold production, the southern Roberts Mountains of the Battle Mountain-Eureka-Cortez gold trend in Eureka County, Central Nevada. The Gold Bar mine is on the same geological structure some 25 miles south of Nevada Gold Mines, a joint venture of Barrick and Newmont. This Cortez-Goldrush complex contains estimated reserves and resources of greater than 50 million gold ounces. Its annual gold production is 1,000,000 ounces.

Gold Bar had been previously mined, between 1991 and 1994, producing 134,000 gold ounces. MUX built a new facility in 2019. The open pit mine was expected to be a large contributor to MUX’s revenue and gold production, however operating challenges arose that reduced gold production and drove cost/oz unacceptably high. Mining activities have shifted recently to a nearby, satellite deposit called Gold Bar South (GBS). Going forward the expectations are higher gold production and lower operating cost/oz as a result of mining a higher ore grade (concentration of gold per ton) and having to move half the amount of material to capture an ounce of gold.

“At Gold Bar, we are looking forward to starting to mine our GBS deposit this quarter,” McEwen said in a November 2022 release. “We are expecting to have a much lower cost/oz than our YTD cost because we will be mining higher grade ore at GBS, with half the strip ratio and no problematic carbonaceous material.”

The Gold Bar Mine will account for approximately 28% of McEwen Mining’s 2023 total attributable production, with guidance pegged at 45,000 GEOs. Most of Gold Bar production in 2023 will be from GBS.

El Gallo/Fenix

Project Fenix is the proposed redevelopment plan for McEwen Mining’s El Gallo Complex in Mexico. There is a long history of mining in this region. MUX’s involvement began in 2013 operating it as an open pit, heap leach mine which produced 281,000 gold equivalent ounces at average cash cost of $655 per ounce. However, due to the transition to deeper sulfide mineralization that is not amenable to heap leaching, mining activities ceased in the second quarter of 2018. The redevelopment envisions constructing a mill at the existing mine site that will initially reprocess the existing heap leach material then transition to open pit mining and processing the sulphide mineralization. The company recently acquired a complete process plant on very advantageous terms that has considerably reduced the projected capital requirements for the project.

CEO Rob McEwen stated in a news release, “This acquisition has made Fenix more attractive to build and could provide a new long life mine for McEwen Mining.”

The initial development approach is to build a mill to reprocess the material on the heap leach pad and produce approximately 17,000 oz of gold annually for eight years. Construction of the Fenix project is expected to be completed by early 2024.

Mine San José

McEwen Mining is a 49% owner and non-operator of the San José gold and silver mine located in Santa Cruz province, Argentina. This high-grade underground mine has been operating since 2007 and currently has an expected life of six years with a reserve grade of 342 gpt silver and 5.7 gpt gold and a resource grade of 427 gpt silver and 7.0 g/t gold.

“The San José mine, where we have a 49% interest, put in a strong quarter and its exploration is continuing to extend its high-grade veins and discover new veins,” McEwen noted in a news release.

Production guidance for 2023 for MUX’s 49% is 70,000 GEOs, 44% of MUX’s total production. As a minority shareholder in the mine, MUX equity accounts for its investment in San Jose, and it receives 49% of the dividends from the mine’s free cash flow.

Market Outlook

Mining stocks took a beating in the wake of the COVID-19 pandemic. However, that could change, as many analysts are now forecasting a gold bull market in 2023.

“The operating challenges we faced in recent years have severely damaged our credibility with our shareholders and the market. As a result, few investors have taken a close look recently at our assets,” Rob McEwen said in a news release. “If they did, I believe some would see the potential value that I see today… I believe there is considerable potential value in MUX, and that is a big reason why I have a personal financial commitment of $220 million in MUX and McEwen Copper.”

Management Team

Robert R. McEwen is Chairman, CEO and Chief Owner of McEwen Mining. He has been associated with the gold industry all his career, with his first 18 years in the investment industry and, since 1990, as CEO of several gold mining companies. He founded Goldcorp and took that company from a $50 million market capitalization to more than $8 billion. He owns 17% of McEwen Mining and is in complete alignment with investors – the cost of his investment in MUX and McEwen Copper is $220 million and he takes an annual salary of only $1. He was awarded the Order of Canada and the Queen Elizabeth’s Diamond Jubilee Award, was inducted into the Mining Hall of Fame, was named an Ernst and Young Entrepreneur of the Year and has Honorary Doctor of Law degrees from York University and Western University.

William Shaver is interim COO and a Director of McEwen Mining. He has decades of management and executive experience in mine design, construction and operations. He was a founder of Dynatec Corporation, which became one of the leading contracting and mine operating groups in North America. In 2013, he was recognized as Ernst and Young Entrepreneur of the Year. Most recently, he served as COO of INV Metals. He is a Professional Engineer with a B.Sc. in Mining Engineering from Queens University.

Perry Ing is interim CFO at McEwen Mining. He has 25 years of experience in the Canadian mining industry. Over the past 15 years, he has held positions as CFO of Mountain Province Diamonds, Kirkland Lake Gold and McEwen Mining. Prior to that, he worked at Barrick Gold and Goldcorp and started his career in the mining practice at PwC. He has a Bachelor of Commerce from the University of Toronto and is a Chartered Professional Accountant in Canada and Certified Professional Accountant in the U.S.

Adrian Blanco S. is the company’s Director – America and Mexico Operations. He has extensive international experience in several industrial sectors and has held executive positions in Mexico, the United States, Peru and Argentina. He joined the McEwen Mining team in 2015 and has led a successful business transformation toward operational discipline, best business practices and financial profitability at subsidiaries Compañia Minera Pangea and McEwen Mining Nevada. He graduated from an Executive Management Program at IPADE and Harvard Business School.

Michael Meding is Vice President and General Manager of McEwen Copper. He has over 20 years of international experience, primarily with major mining companies such as Barrick Gold and Trafigura, including extensive experience with project development and operations in Argentina. While at Barrick Gold’s Veladero mine in Argentina, Mr. Meding played a key role in the turnaround, extension of the mine life and subsequent strategic partnering with Shandong Gold. He holds an MBA from Indiana University in Pennsylvania and an MBA from the Leipzig Graduate School of Management in Germany.

McEwen Mining Inc. (NYSE: MUX), closed Monday's trading session at $2.05, up 3.0151%, on 73,251 volume with 375 trades. The average volume for the last 3 months is 57,207 and the stock's 52-week low/high is $1.04999995/$5.63000011.

Recent News

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF)

The QualityStocks Daily Newsletter would like to spotlight Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF).

Oregon became the first state in the United States to allowpsychedelic use after it legalized the use of psilocybin by adults in 2020. A psychedelic compound that occurs in magic mushrooms, psilocybinis one of many other psychedelics that are said to have immensepotential as effective mental-health treatments. Initial studieshave shown that psilocybin may be able to alleviate the symptoms of mental health conditions, including anxiety, depression andsubstance-use disorder, especially when paired with psychotherapy.Generally, psychedelic-assisted therapy involves undergoing a psychedelic experience under a trainedphysician followed by several hours of counseling to teach thepatient how to integrate any insights they had during theexperience into their lives. However, since thepsychedelic-assisted therapy industry is still in its infancy,there aren’t many physicians and therapists who are adequatelytrained on how to guide patients through psychedelic experiences orthe integration process. As entities such as Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) expand their footprint, they could also tap the human resourcebeing trained at centers such as the Synaptic Training Institute.

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation. The company owns and operates an umbrella of related businesses, including trusted media and e-commerce platforms like Reality Sandwich and Delic Radio; Delic Labs, the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology; Meet Delic, the premiere psychedelic wellness event; and Ketamine Infusion Centers, one of the largest ketamine clinics in the country.

Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and treatment options to the masses. Its founders helped build the multi-billion-dollar cannabis industry and aim to do the same in psychedelics as it follows a similar path toward legalization. In its quest to advance the new psychedelic renaissance upon us, Delic has become the pioneer in its field, creating an ecosystem of opportunities by investing in cutting-edge ideas.

The Vancouver-based company was formed in 2019 to address the growing interest in psychedelic wellness backed by science. Delic was the ‎first psychedelic umbrella platform. It is currently a trusted source for those interested in ‎psychedelic culture, education, treatments, and more.

While other emerging companies focus on patent medicine and big pharma for substances limited by government regulation, Delic is blazing a unique trail. It identifies ancillary and fully legal opportunities like IP, new media, live events, ketamine clinics (with the ability to offer additional psychedelic treatments once legalized, and large-scale production and brings them under its big tent of resources and reach.

The Big Problems Delic Is Addressing

  • Fifty percent of Americans will meet the criteria for a mental health condition sometime in their lifetime. The FDA has approved psilocybin therapy as a breakthrough therapy for depression.
  • Every 40 seconds, someone in the world commits suicide. Ketamine has been shown to decrease thoughts of suicide significantly. In 2019, the FDA approved esketamine as a fast-acting antidepressant.
  • Traditional palliative care methods do not eradicate end-of-life (EOL) anxiety. LSD and psilocybin have been shown to reduce EOL anxiety for terminally ill patients. Eighty percent of terminally ill patients with psilocybin sessions experienced significant reductions in depression and anxiety.
  • Approximately 50 million people in the U.S. are addicted to some tobacco product. Research shows that psilocybin is helping people quit smoking.

The Delic Ecosystem

The Delic Ecosystem covers three main areas: media, health, and science. The media focus is educating and motivating the masses through a variety of digital platforms, like Delic’s Reality Sandwich digital magazine, a free public education platform providing psychedelic guides, news and ‎culture (1.4+ million page views in 2020 and 54k social media followers across all platforms); Meet Delic, the first-ever psychedelic wellness summit and the premier psychedelic wellness event based in Las Vegas (over 2,000 live attendees and 5,000+ email subscribers); and Delic Radio (over 43 episodes and 100k total streams). Delic has also been featured in numerous media outlets like Forbes, NBC News, The Joe Rogan Experience, Daily Beast, High Times, and The Dr. Drew Podcast.

The focus of Delic’s health operations is the most accessible psychedelic treatments that can help billions of people live happier lives. Delic does this through one of the largest ketamine clinic chains in the country, Ketamine Infusion Centers (KICs), a limited liability corporation formed under the laws of Arizona that runs three ketamine clinics located in Bakersfield, California, and Phoenix, Arizona. Its management team has over 15 years of experience in the clinic and medical space, scaling and operating over 20 clinics, with a plan to open 10 more clinics in the next 18 months. Together, these clinics have overseen 4,000+ treatments delivered to date.

The focus of Delic’s science operations is developing IP and advanced extraction and testing facilities that are the backbone of the legal market. Delic carries this out through Delic Labs, a licensed cannabis and psilocybin research laboratory based in Vancouver. It’s the only entity licensed by Health Canada to exclusively focus on research and development of psilocybin vaporization technology.

Founded by award-winning chemists, Delic Labs focuses on extraction optimization, analytical testing, and chemical process development to advance the cannabis and psilocybin industries. Health Canada gave it a Section 56 Exemption to work with psilocybin compounds, allowing the company to possess and research these products for development and quality control before they hit the market.

Latest Acquisition – Homestead Book Company

On March 4, 2021, Delic announced its acquisition of Seattle-based Homestead Book Company. Homestead is a legacy counterculture distributor of psychedelic media. It’s also the creator of one of the first self-contained psilocybin mushroom grow kits.

The acquisition of Homestead is an exciting one, as it shows how Delic is increasing accessibility to this nascent industry within regulated jurisdictions. Homestead has sold tens of thousands of mushroom kits globally and was one of the earliest distributors for High Times and many other counterculture publications.

The Homestead acquisition allows Delic to increase its product offerings on its website, Reality Sandwich, which recently hit a record for average monthly traffic of over 200,000 unique visitors and over 2.6 million active readers in 2020.

Market Outlook

The psychedelic renaissance is here. Just in time to help address the global mental health crises, plant medicines have the potential to help billions of people live happier lives. Thanks to university-led and FDA-approved studies, North America is leading the way in advancing an industry as psychedelics are becoming accepted globally for therapeutic, medical, and recreational use. Here are some statistics:

  • 32 million people in the U.S. have used psychedelics at least once
  • 17% of all American adults between 21 and 64 have used psychedelics at least once
  • $500 billion is spent in the U.S. every year on prescription drugs
  • $238 billion is spent in the U.S. every year on mental health treatments and ancillary services
  • The anxiety disorder and depression treatment market is estimated at $16 billion
  • $187.8 billion was spent in 2013 on mental health and substance abuse disorders

Management Team

Delic Co-Founder and CCO Jackee Stang was an executive at High Times, a leading counterculture publication that became the voice for the cannabis industry. The monthly magazine had a circulation of over 500,000 copies per issue. Its website attracted 500,000 to five million users each month by 2014.

Likewise, company Co-Founder and CEO Matt Stang was a previous owner and operator of High Times, a position from which he played an instrumental in legalizing cannabis in multiple states and launched the Cannabis Cup in America. After interacting with the cannabis community for two decades, he helped found Delic in 2019 as one of the first psychedelic corporations. He shapes the company’s vision and path using his expertise in branding, marketing, business development, and product viability.

Delic’s VP of Business Development, John Coleman, Ph.D., is a former president of Anandia Labs, a biotech company focused on genetics and analytics. Having experience in both science and business, Dr. Coleman is well-equipped to lead Delic’s business development efforts as it strives to enter new vertical markets.

Zak Garcia is the company’s Chief Marketing Officer. He was the former CMO of Bulletproof Inc., maker of the well-known Bulletproof Coffee brand. Mr. Garcia is a marketing and leadership strategist who helped grow Bulletproof Coffee to over $250 million in revenue.

Delic Holdings Corp. (DELCF), closed Monday's trading session at $0.0336, off by 11.3456%, on 94,004 volume. The average volume for the last 3 months is 94,004 and the stock's 52-week low/high is $0.022/$0.1076.

Recent News

Jupiter Wellness Inc. (NASDAQ: JUPW)

The QualityStocks Daily Newsletter would like to spotlight Jupiter Wellness Inc. (NASDAQ: JUPW).

Jupiter Wellness (NASDAQ: JUPW), a company focused on hair, skin and sexual wellness, todayannounced availability of its redeemable digital coupons forshareholders of record to claim on Upstream’s trading app. Uponsuccessful claim, shareholders may redeem the digital coupon for agift package of company products valued at over $179 or trade withothers globally on Upstream to bring new potential customers intothe community. The announcement reads, “By incorporating Upstream’sWeb3 digital coupons into our strategy, we aim to provide ourshareholders with first-hand experience of our products and bringnew potential customers into our community to drive additionalengagement, revenue and sales to Jupiter Wellness.”

To view the full press release, visit https://ibn.fm/sWwHz

Jupiter Wellness Inc. (NASDAQ: JUPW) is a diversified company that supports health and wellness by researching and developing over-the-counter (OTC) products and intellectual property. The company has a robust and growing portfolio of granted and pending patents to protect its proprietary products.

Jupiter Wellness’s product pipeline, backed by clinical research to ensure efficacy, addresses a range of underserved conditions. The company’s revenue is generated through a combination of OTC and consumer product sales, contract research agreements, and licensing royalties.

Jupiter Wellness was formed in 2018 and is headquartered in Jupiter, Florida.

Products with Purpose

Jupiter Wellness’s product pipeline currently targets a variety of indications with underserved needs. These include:

  • Hair Loss – Jupiter Wellness’s Minoxidil Booster is a topical treatment that’s been clinically shown to increase the enzymes needed for minoxidil to work by up to 7x over a two-week period. The product has been licensed to Taisho, a $2.6 billion revenue company and Japan’s leading seller of minoxidil products, which expects to launch it commercially in 2023. The product is licensed to India-based Cosmofix Technovation Pvt. Ltd. and Sanpellegrino Cosmetics, and additional licensing opportunities are being pursued.
  • Psoriasis & VitiligoPhotocil safely and effectively permits phototherapy treatments at home by blocking harmful radiation and permitting the passage of therapeutic UV radiation. The product has been licensed abroad and is currently being launched commercially in India by Eris Oaknet Healthcare and Cosmofix Technovation under the brand name PhotoFirst. The product is also available in the U.S., and the company is working to find new partners in dermatology for expanded distribution.
  • Jellyfish Protection SunscreenNoStingz is a topical protection from jellyfish, sea lice, and UVA/UVB rays. It provides an effective barrier against the stinging mechanism of jellyfish cnidocytes, preventing the delivery of venom to the victim. NoStingz is currently available online through Amazon and Walmart, as well as in select stores.
  • EczemaJW-100 is a pre-revenue topical treatment for atopic dermatitis (eczema). In prior studies, JW-100 cleared or reduced eczema symptoms following 2 weeks of use. Results suggest that JW-100 may potentially prove superior to existing prescription drugs. It is currently being evaluated in a Phase 3, double-blind, placebo-controlled multicenter trial.
  • BurnsJW-300 is a pre-revenue topical treatment for first-degree burns and sun exposure. In prior studies, JW-300 was shown to significantly lower the incidence of burns in patients exposed to UV radiation. It is currently being evaluated for sale as an “after sun” consumer product.
  • Cold SoresJW-400 is a pre-revenue topical treatment of herpes labialis (cold sores). A phase 1, double-blind, placebo-controlled investigational study is currently being planned for JW-400.
  • Sexual WellnessJW-500 is a pre-revenue topical treatment for female libido loss. In clinical studies, the topical formulation improved nipple sensitivity and alleviated associated sexual problems. Jupiter Wellness plans to file for a pre-IND meeting with the U.S. FDA within the next 12 months and intends to seek Orphan Drug Designation.
  • COVID-19-Induced TinnitusJW-600 is currently being evaluated in a triple-blind clinical study. Up to 15% of patients recovering from COVID-19 have experienced post-acute COVID-19-induced tinnitus

Management Team

Brian John is the CEO of Jupiter Wellness. For the past 20 years, he has been an investor and advisor to companies around the globe. He is the founder of a successful financial consulting firm specializing in helping emerging growth companies and has worked with hundreds of companies in dozens of countries over the last 25 years. Mr. John also serves on the board of directors of The Learning Center at the Els Center of Excellence – a school for children with autism in Jupiter, Florida.

Doug McKinnon is the CFO of Jupiter Wellness. His 35+ year professional career includes financial, advisory, and operational experience across a broad spectrum of industry sectors, including oil and gas, technology, cannabis, and communications. He has served in C-Level positions in both private and public sectors, including as chairman and CEO of an American-stock-exchange-traded company; as VP – Chief Administrative Officer of a $12-billion-market-cap Nasdaq-traded company; as CFO of several publicly-held U.S., Canadian and Australian companies; and as CEO/CFO of various other private enterprises.

Dr. Glynn Wilson is the Chief Scientific Officer of Jupiter Wellness. He brings to the company an extensive background of success in corporate management and product development with tenures in both multinational and start-up biotech organizations. He was formerly Head of Drug Delivery at SmithKline Beecham Pharmaceuticals; Research Area Head in Advanced Drug Delivery at Ciba-Geigy Pharmaceuticals; and Founder, CEO, and Chairman of TapImmune Inc., which became Marker Therapeutics through a merger. At TapImmune, he licensed cancer vaccine technology platforms and established the clinical pipeline.

Jupiter Wellness Inc. (NASDAQ: JUPW), closed Monday's trading session at $2.05, up 3.0151%, on 73,251 volume with 375 trades. The average volume for the last 3 months is 57,207 and the stock's 52-week low/high is $1.04999995/$5.63000011.

Recent News

Cepton Inc. (NASDAQ: CPTN)

The QualityStocks Daily Newsletter would like to spotlight Cepton Inc. (NASDAQ: CPTN).

Built upon its predecessor–Vista-X90 lidar–that is being used inCepton's flagship ADAS lidar program with GM and Koito, theVista-X120 Plus is designed to significantly enhance lidarperformance without compromising reliability, size, powerefficiency, and cost

Vista-X120 Plus advances the company's vision of enabling safe andautonomous transportation for everyone through mass-market lidaradoption.

As a member of the Lidar Coalition, Cepton showcased its newproduct and a comprehensive portfolio of its lidar solutions at CES2023, one of the most influential tech events in the world; thecompany demonstrated its adaptive 3D perception and simulationsfeaturing a Chevy Silverado and a Ford F-150 equipped with Cepton’slatest vehicle integration solutions

Cepton (NASDAQ: CPTN) was one of the firsts to scale lidar for high-volume,multi-vehicle model deployment through our flagship lidar program,"said Dr. Jun Pei, CEO, and Co-Founder of this Silicon Valleyinnovator of high-performance lidar solutions, as he announced thelaunch of the company's latest innovative product – a newgame-changing lidar called Vista(R)-X120 Plus (https://ibn.fm/rB4a9). "Utilizing OEM-validated building blocks, the Vista-X120 Plusaims to enhance vehicle safety across all levels of automation.This pathbreaking lidar is positioned to quickly hit the massmarket and enable the precision needed for autonomous driving at asafety level that every consumer deserves," Pei continued as herevealed specifics about Cepton's new product addition claimed bythe company to be the world's slimmest software-definable, top-tierautomotive lidar for real-time adaptive 3D perception (https://ibn.fm/POpek).

Cepton Inc. (NASDAQ: CPTN) is a provider of state-of-the-art, intelligent, lidar-based solutions serving a range of markets, including automotive (ADAS/AV), smart cities, smart spaces and smart industrial applications. General Motors (NYSE:GM) has granted a series production award for Cepton’s lidar, the biggest such award to date in the automotive space. Cepton’s is the lidar component of GM’s Ultra Cruise autonomous driving platform. By leveraging its patented Micro Motion Technology (MMT®) lidar platform, the company develops reliable, scalable and cost-effective solutions that deliver long-range, high-resolution 3D perception for smart applications.

Cepton was established in 2016 by co-founders Dr. Jun Pei and Dr. Mark McCord. The company is headquartered in San Jose, California, and serves a fast-growing customer base through an international presence spanning North America, Germany, Japan, India and China.

Micro Motion Technology (MMT®)

Cepton was built from the ground up to meet key lidar industry challenges for mass market adoption. This company’s portfolio of proprietary technology is uniquely aimed at facilitating this industry growth through a combination of performance, reliability, affordability and design integration.

Key among its innovations is MMT®, a mirrorless, frictionless, rotation-free 3D imaging platform designed specifically for lidars. Its benefits for OEMs and system integrators include:

  • Reliability – The durable design uses common, easily attainable materials.
  • Versatility – The platform is capable of achieving near- to ultra-long range with a wide field of view.
  • Efficiency – MMT® features a compact form factor, low power usage and inexpensive components.
  • Scalability – Its simple design means that scale-up to high manufacturing volumes is easily attainable.

Because of their compact form factor, Cepton lidars are embeddable and ideally suited for advanced driver-assistance system (ADAS) integration, whether behind windshield, in headlamp or in fascia.

Agreement with KOITO

KOITO Manufacturing Co. Ltd., the world’s premier Tier 1 auto lighting supplier, originally started an evaluation of Cepton’s MMT® based lidars in 2018. In 2020, KOITO made an investment in Cepton aimed at accelerating the company’s development and enabling KOITO’s industrialization of high-performance and high reliability lidar sensors for ADAS and autonomous vehicle (AV) applications.

Through this collaboration, Cepton was able to secure the largest ADAS lidar series production award[1] with General Motors as a sole source in the automotive space. The award covers GM vehicles for the initial period of 2023-2027.

On August 5, 2021, the two companies deepened their relationship when KOITO committed to invest a further $50 million in Cepton’s business through its participation in a Private Investment in Public Equity (PIPE) offering of shares of common stock of Growth Capital Acquisition Corp. in connection with Cepton’s recent merger.

Collaboration with GM

On July 13, 2021, Cepton announced that it had secured an ADAS lidar series production award from a leading, Detroit-based global automotive OEM – the biggest lidar production award by any OEM to any lidar company. It was later clarified that the OEM was General Motors, and Cepton’s lidar is part of GM’s ADAS Ultra Cruise system.

GM is “expected to deploy Cepton lidars in its next generation of advanced driver assistance systems (ADAS) across multiple vehicle classes and models – not just luxury cars.” As such, the agreement marks the potential for “an industry-first, mass-market adoption of lidar technology for automotive ADAS, with an anticipated deployment in consumer vehicles starting in 2023.”

On July 28, 2021, Ford Motor Company (NYSE: F) distributed an article on Medium noting, “Ford has been engaged with Cepton almost since their inception in 2016, both for R&D collaboration and small-scale deployments. Cepton LiDAR are deployed in some of [Ford’s] smart city projects. Based on Ford’s guidance, Cepton delivered a custom version of their LiDAR to enable R&D on advanced ADAS features.”

Market Outlook

Driven by increasing development and adoption in automobile safety applications, environmental mapping and 3D-modeling, the global lidar market is forecast to experience considerable growth over the coming years. A research report published by MarketsAndMarkets suggests that the sector will grow to an estimated $3.4 billion by 2026, achieving a CAGR of 21.6% over the next five years.

The report further highlights increasing investments in lidar startups by automotive giants as a driver of growth opportunities in the sector, particularly in North America.

In 2020, ground-based lidar accounted for the lion’s share of the overall lidar market, and this trend is expected to continue as the automotive sector continues to rapidly advance adoption across the full spectrum of vehicle classes. One factor not to be underestimated is the high barrier of entry and the exceptionally long time required for automotive OEMs to vet and award a production win to a lidar company. It is a commonly held view that the over 50 lidar companies will inevitably coalesce into a handful serving all OEMs.

Cepton, having a head start through its established partnership with leading global OEM GM, is uniquely positioned to capitalize on this market growth in the years to come.

Management Team

Cepton’s founder-led team is made up of lidar industry pioneers with decades of collective experience across advanced lidar and imaging technologies.

Jun Pei, Ph.D., is the company’s CEO and Co-Founder. He is a technology specialist with a focus in optics and electronics. Prior to founding Cepton, Dr. Pei founded AEP Technology, a firm focused on developing advanced 3D optical instruments. He received his Ph.D. in electrical engineering from Stanford University.

Mark McCord, Ph.D., is Cepton’s CTO and Co-Founder. Prior to founding Cepton, he led advanced development at KLA-Tencor. Dr. McCord also formerly served as an associate professor at Stanford University, where he earned his Ph.D. in electrical engineering.

Winston Fu, Ph.D., is the company’s CFO. Dr. Fu is the founder of Silicon Valley venture capital firm LDV Partners. Prior to joining Cepton, he served as CFO and Chairman of Active-Semi before its acquisition. Dr. Fu has also helped to build many technology companies as an entrepreneur and/or board member. He received his Ph.D. in applied physics from Stanford University, as well as an MBA from the Kellogg School of Management at Northwestern University.

[1] Largest known ADAS lidar series production award based on number of vehicle models awarded

Cepton Inc. (NASDAQ: CPTN), closed Monday's trading session at $1.23, off by 1.6%, on 140,649 volume. The average volume for the last 3 months is 139,530 and the stock's 52-week low/high is $1.01/$80.16.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.